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The endocannabinoid system 
The endocannabinoid system consists of G-protein coupled cannabinoid receptors that can 
be activated by cannabis-derived drugs and small lipids called endocannabinoids (ECs). 
Anandamide and 2-arachidonyl glycerol are considered as the principal ECs; however, the EC 
family also includes alsovirodhamine, noladin ether, N-arachidonoyldopamine (NADA), 
homo-linolenylethanolamide (HEA), docosatetraenylethanolamide (DEA), and other related 
compounds such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). Moreover, 
the endocannabinoid system comprises the genes encoding CBRs, and the enzymes involved 
in their synthesis (NAPE-PLD, PLA2, PLC, DAGL, PI-PLC and Lyso-PLC) and degradation (FAAH, 
MAGL) (Ahn et al, 2008). 
Until few years ago, CB1 has been believed to be the unique CB receptor subtype of the 
brain, limiting the expression of CB2 receptors to the immune system (Belvisi et al, 2008; 
Costa, 2007; Galiegue et al, 1995; Griffin et al, 1999; Howlett et al, 2002; Ibrahim et al, 2003; 
Lynn and Herkenham, 1994; Munro et al, 1993). More recently, CB2 expression in the brain 
and its potential involvement in addiction, eating disorders, neuropsychiatric disorders have 
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been provided (Ishiguro et al, 2010a; Ishiguro et al, 2010b; Ishiguro et al, 2007; Onaivi, 2009; 
Onaivi et al, 2008a; Onaivi et al, 2008b; Roche and Finn, 2010). 
Given their lipidic nature, ECs are not stored in vesicles but are synthesized “on demand” 
from membrane phospholipid precursors in response to an increase in postsynaptic 
intracellular calcium ([Ca2+]i) alone, or combined with activation of postsynaptic GPCRs, such 
as group I metabotropic glutamate receptors (mGluRs) (Maejima et al, 2001; Varma et al, 
2001) or M1/M3 muscarinic acetylcholine receptors (mAChRs) (Kim et al, 2002; Ohno-
Shosaku et al, 2003) and immediately released from postsynaptic neurons. They travel 
retrogradely through the synaptic cleft and engage presynaptic cannabinoid receptors, 
generally suppressing neurotransmitter release from axon terminals (Wilson and Nicoll, 
2001b). In some regions, e.g., hippocampus and amygdala, the highest densities of CB1 
receptors are on axon terminals of interneurons co-expressing GABA and cholecystokinin 
(CCK) (Katona et al, 1999; Marsicano and Lutz, 1999). In other regions, such as in the 
cerebellum, CB1 receptors are more equally distributed on both excitatory and inhibitory 
terminals 
Increases in postsynaptic [Ca2+]i typically triggers short-term forms of CB1-mediated 
suppression of synaptic transmission: depolarization-induced suppression of inhibition (DSI) 
(Ohno-Shosaku et al, 2001; Wilson et al, 2001b) or excitation (DSE) (Kreitzer and Regehr, 
2001) based on the type of terminals involved. Both DSI and DSE are mediated by brief 
(~secs) stimulation of CB1 receptors, which prevents transmitter release by increasing K+ 
conductance (Kreitzer et al, 2002) or by inhibiting voltage-gated Ca2+ channels (Diana et al, 
2002; Hoffman and Lupica, 2000; Kreitzer et al, 2001; Wilson et al, 2001a). On the other 
hand, pharmacological activation of mGlu receptors triggers CB1-mediated long-term 
synaptic depression (ECs-LTD), during which the synaptic transmission is reduced 
(Chevaleyre and Castillo, 2003; Gerdeman et al, 2002). 
Endocannabinoid system, memory and cognition 
Due to the localization of cannabinoid receptors in brain regions such as the 
hippocampus, the basolateral amygdala and the prefrontal cortex (Breivogel and Childers, 
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1998; Katona, 2009; Mackie, 2005), which are strictly associated with both cognitive and 
emotional processes  (Laviolette and Grace, 2006a; McLaughlin and Gobbi, 2011; Tan et 
al, 2011; Viveros et al, 2007) and to the capability of the endocannabinoid system to 
modulate synaptic plasticity, it is not surprising that this system could play a pivotal role 
in the modulation of emotional memory processing. 
It is well establish that CB1 receptors are importantly involved in neural plasticity 
mechanisms related to the processing, consolidation and extinction of emotionally salient 
cognitive events (Abush and Akirav, 2010; Akirav, 2011; Campolongo et al, 2009a; 
Campolongo et al, 2009b; Laviolette et al, 2006a; Laviolette and Grace, 2006b; Mackowiak et 
al, 2009; Marsicano et al, 2002). Animal studies have demonstrated that the 
endocannabinoid system may affects short-term memory by altering the mechanisms 
responsible for these processes within the hippocampus, by selectively affecting encoding 
processes (Barna et al, 2007). Moreover, the important involvement of other subcortical 
structures, for instance the amygdala, in the modulation of the memory consolidation 
mechanism in an endocannabinoid-dependent manner processes has been firmly 
established as well (Campolongo et al, 2009b). 
Outline 
In the first 2 years of the PhD program , at the Department. of Physiology and 
Pharmacology “V. Erspamer” – Sapienza University of Rome, I have investigated the role 
of the endocannabinoid system in the regulation of emotional memory processes in rats. 
In a first line of research I have focused my attention on the effects induced by general 
anaesthetics on memory consolidation and their putative interaction with the 
endocannabinoid system. There is extensive evidence that the occurrence of traumatic 
experiences associated with perioperative awareness or intensive care unit ICU treatment 
could result in stress-related disorders such as posttraumatic stress disorder and impaired 
long-term health-related quality of life outcomes (Kapfhammer et al, 2004a; Schelling et 
al, 2003). In order to identify whether anaesthetic drugs, used in ICU, could be 
responsible of these effects, in Chapter 1, I have investigated the effects of propofol on 
memory consolidation of aversive events. Propofol is a a commonly used agent for 
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general anaesthesia and for sedation in patients undergoing intensive care treatment 
(Jones et al, 2007) and known to exert inhibitory action on fatty acid amide hydrolase, the 
enzyme that degradesthe endocannabinoid anandamide (Patel et al, 2003).  
In Chapter 2 I have investigated the effect induced by the prototypical endocannabinoid 
transport inhibitor, AM404, on memory recognition and short-term memory and whether 
such effects depend on different levels of emotional arousal. This study was expired by 
the evidence that cannabinoid compounds may influence emotional processes depending 
on the level of environmental aversiveness at the time of drug administration (Haller et 
al, 2009).  
Growing evidence demonstrates that the endocannabinoid system in the basolateral 
complex of the amygdala (BLA) is one important actor generating and coordinating 
emotional cognitive responses (Campolongo et al, 2009b; Lee et al, 2006a, b; Milton et al, 
2008a; Milton et al, 2013; Theberge et al, 2010).  
In order to expand these findings, I spent the third year of my PhD program in the 
laboratory directed by Prof. Barry Everitt at Department of Psychology, Downing College, 
University of Cambridge, UK. My research in Everitt’s lab evaluated the role of the 
endocannabinoid system in the BLA in the reconsolidation of conditioned fear memory 
using a classic Pavlovian conditioning approach. Memory reconsolidation is the process by 
which previously consolidated memories become destabilized at retrieval, and require 
restabilization in order to persist in the brain (Lewis, 1979; Nader, 2003). Previous 
findings suggest that pharmacological manipulation before or immediately after retrieval, 
could prevent (Debiec et al, 2002; Nader et al, 2000; Taubenfeld et al, 2009; Wang et al, 
2009) or enhance the expression of conditioned fear responses (Lee et al, 2006b). In 
Chapter 3 we firstly elucidated the neurochemical basis of reconsolidation processes - 
destabilization and restabilization - and the role of different subtypes of NMDAR, GluN2B-
NMDARs andGluN2A-NMDARs in BLA. Subsequently, in Chapter 4, we studied how the 
manipulation of reconsolidation process by altering the endogenous cannabinoid tone in 
BLA after retrieval could influence expression of fear-related response. 
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Chapter 5, summarizes and discusses the findings of this thesis and provides conclusions 
and future perspectives. 
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ABSTRACT 
Background: Propofol is associated with postoperative mood alterations and induces a 
higher incidence of dreaming compared with other general anesthetics. These effects 
might be mediated by propofol’s inhibitory action on fatty acid amide hydrolase, the 
enzyme that degrades the endocannabinoid anandamide. Because propofol is also 
associated with a higher incidence of traumatic memories from perioperative awareness 
and intensive care unit treatment and the endocannabinoid system is involved in 
regulating memory consolidation of emotional experiences, the authors investigated 
whether propofol, at anesthetic doses, modulates memory consolidation via an activation 
of the endocannabinoid system.  
Methods: Male Sprague-Dawley rats were trained on an inhibitory avoidance task in 
which they received an inescapable foot shock upon entering the dark compartment of 
the apparatus. Drugs were administered intraperitoneally immediately or 30, 90, or 
180min after training. On the retention test 48 h later, the latency to reenter the dark 
compartment was recorded and taken as a measure of memory retention.  
Results: The anesthetic doses of propofol administered after training significantly 
increased latencies of 48-h inhibitory avoidance performance (483.4  181.3, 432.89  
214.06, 300 and 350 mg/kg, respectively; mean  SD) compared with the corresponding 
vehicle group (325.33  221.22, mean  SD), which is indicative of stronger memory 
consolidation in propofol treated rats. Administration of a non-impairing dose of the 
cannabinoid receptor antagonist rimonabant blocked the memory enhancement induced 
by propofol (123.39  133.10, mean  SD). Delayed administration of propofol 90 and 180 
min after training or immediate posttraining administration of the benzodiazepine 
midazolam or the barbiturate pentobarbital did not significantly alter retention.  
Conclusions: These findings indicate that propofol, in contrast to other commonly used 
sedatives, enhances emotional memory consolidation when administered immediately 
after a stressful event by enhancing endocannabinoid signaling. 
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Introduction 
Propofol is a commonly used agent for general anesthesia and for sedation in patients 
undergoing intensive care treatment (ICU). It is known to reduce postoperative nausea 
and vomiting1 and is associated with postoperative mood alterations and a higher 
incidence of dreaming compared with other general anesthetics. However, the use of 
propofol for general anesthesia or for sedation of critically ill patients in the ICU is not 
universally successful with respect to preventing traumatic memories from perioperative 
awareness and ICU treatment2. There is extensive evidence that the occurrence of 
traumatic experiences associated with perioperative awareness or ICU treatment could 
result in stress-related disorders such as posttraumatic stress disorder and impaired long-
term health-related quality of life out comes3,4. One clinical study, investigating propofol’s 
effects on memory, reported that propofol inhibits conscious memory processing in 
human subjects soon after memory encoding and that it impairs the encoding of material 
into long-term memory.5 In another study, propofol administration to rats induced 
amnesia of training on an inhibitory avoidance task.6 However, in both studies propofol 
was administered before learning, thus revealing propofol’s effect on the encoding of new 
information. No studies are available regarding propofol’s effects on the consolidation of 
traumatic memories. However, because patients often have experienced stressful events, 
such as preoperative fear and anxiety, car accidents, myocardial infarctions, or acute 
respiratory distress shortly before induction of general anesthesia or sedation with 
propofol, it is crucial to investigate the effects of propofol administered shortly after the 
acquisition of new information, a time window when the memory trace is consolidated 
into stable long-term memory. Propofol inhibits the enzyme fatty acid amide hydrolase, 
which is known to degrade endocannabinoids, especially anandamide.7 Like propofol, the 
endocannabinoid system recently has been shown to be crucially involved in mood 
control in animals 8,9 and the regulation of nausea and vomiting in humans during stress.10 
Thus, some of the mentioned propofol effects could be attributable to an activation of the 
endocannabinoid system. 11 Propofol administration to mice has been shown to increase 
endocannabinoid content within the brain, an effect that could not be detected with 
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other sedative agents, such as midazolam or thiopental.7 In addition, endocannabinoid 
plasma concentrations increased moderately in patients undergoing propofol anesthesia 
but decreased in patients undergoing general anesthesia with a volatile agent such as 
sevoflurane 12 or isoflurane.13 The endocannabinoid system consists of endocannabinoid 
ligands, the endogenous cannabinoid receptors 1 and 2 (CB1 and CB2), and enzymes 
involved in the synthesis and metabolism of endocannabinoids.14 Endocannabinoids (i.e., 
anandamide and 2-arachidonoylglycerol) are synthesized on demand through cleavage of 
membrane precursors and serve as retrograde messengers at central synapses.15 They 
bind to CB1 receptors on axon terminals to regulate ion channel activity and 
neurotransmitter release 16 and are degraded intracellularly by specific enzymes: 
anandamide is mainly degraded by fatty acid amide hydrolase and 2-arachidonoylglycerol 
by monoacylglycerol lipase.17 CB1 receptors are highly expressed in several brain regions 
and in lower densities outside the brain.18,19 In contrast, CB2 receptors have a more 
restricted distribution and are found mainly on immune cells and in low numbers in the 
brainstem20 and some other brain regions.21 Both CB1 and CB2 receptors primarily signal 
through inhibitory G proteins.22 Recent evidence indicates an important role for 
endocannabinoids and CB1 receptor activation in enhancing the memory consolidation of 
emotionally arousing experiences.23,24 Moreover, it recently has been shown that the fatty 
acid amide hydrolase inhibitor URB597 enhances memory acquisition and consolidation in 
rats.2 These findings suggest that propofol might modulate memory consolidation of 
emotionally arousing experiences via an interaction with the endocannabinoid system. To 
investigate this issue, in a first experiment, anesthetic doses of propofol were 
administered to rats by intraperitoneal injection, immediately and 30, 90, and 180 min 
after aversively motivated inhibitory avoidance training, a widely used animal model to 
assess drug effects on emotional memory consolidation. In a second experiment, we 
evaluated whether the propofol effect on the consolidation of inhibitory avoidance 
memory is specific for this anesthetic by administering anesthetic doses of the 
benzodiazepine midazolam or the barbiturate pentobarbital immediately after inhibitory 
avoidance training. In the last experiment, we investigated whether the memory-
enhancing effect of propofol depends on concurrent CB1 activity by administering a 
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nonimpairing dose of the CB1 receptor antagonist rimonabant 30 min before Propofol 
injection; we also studied whether propofol administration modulates endocannabinoid 
release in rats.  
Materials and Methods 
Animals 
Male adult Sprague-Dawley rats (350–450 g at the time of training; Charles River 
Laboratories, Calco, Italy) were housed individually and maintained in a temperature-
controlled environment (20°  1°C) under a 24-h light-dark cycle (7:00 AM to 7:00 PM lights 
on) with unlimited access to food and water. All procedures involving animal care or 
treatments were approved by the Italian Ministry of Health (Rome, Italy) and performed 
in compliance with the guidelines of the US National Institutes of Health and the Italian 
Ministry of Health (D.L. 116/92), the Declaration of Helsinki, and the Guide for the Care 
and Use of Mammals in Neuroscience and Behavioral Research (National Research Council 
2004).  
Drug Treatment 
2,6-Diisopropyl phenol (propofol, 250, 300, or 350mg/kg), purchased from Sigma-Aldrich 
(Milan, Italy), was dissolved in a vehicle containing 100%sesame oil. Midazolam(30, 50, or 
70 mg/kg; Ratiopharm, Ulm, Germany) was dissolved in saline, and pentobarbital (60, 70, 
or 80 mg/kg; Sigma-Aldrich, St. Louis, MO) was dissolved in a vehicle containing 40% 
propylene glycol (1,2-propanediol), 10% ethanol, and 50% distilled water. Drug solutions 
were freshly prepared before each experiment and administered by intraperitoneal 
injection in a volume of 1 ml/kg immediately after the training trial. To control for time 
specificity, propofol was administered to different groups of rats either 30, 90, or 180 min 
after the training trial. To assess whether CB1 receptors are involved in mediating the 
propofol effect on memory consolidation, the CB1 receptor antagonist rimonabant (1 
mg/kg; donated by the National Institute of Mental Health, Chemical Synthesis and Drug 
Supply Program, Bethesda, MD) was dissolved in a vehicle containing 5% polyethylene 
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glycol, 5% TWEEN 80, and 90% saline9 and administered immediately after training, 
whereas propofol was given 30 min later.  
Behavioral Studies 
Inhibitory Avoidance Apparatus and Procedures. Rats were trained and tested in an 
inhibitory avoidance apparatus consisting of a trough-shaped alley (91 cm long, 15 cm 
deep, 20 cm wide at the top, and 6.4 cm wide at the bottom) divided into two 
compartments, separated by a sliding door that opened by retracting into the floor. The 
starting compartment (31 cm long) was made of opaque white plastic and illuminated by 
a lamp; the shock compartment (60 cm long) was made of two dark, electrifiable metal 
plates and was not illuminated.26 Training and testing were performed during the light 
phase, between 10:00 AM and 2:00 PM, and were conducted in dim light conditions in a 
sound-attenuated room. Animals were handled 1min each for 2 days before the training 
day. For training, the rats were placed into the starting compartment of the apparatus, 
facing away from the door, and were permitted to explore the apparatus. After the rats 
stepped completely into the dark compartment, the sliding door was closed and a single, 
inescapable foot shock (0.35 mA) was delivered for 1 s. The animals were removed from 
the shock compartment 15 s after termination of the foot shock. Retention was tested 48 
h later. On the retention test trial, the rats were placed into the starting compartment, 
and the latency to reenter the shock compartment with all four paws (maximum latency 
of 600 s) was recorded and used as a measure of retention. Longer latencies were 
interpreted as indicating better retention.27 Immediately after the training and testing of 
each animal, the apparatus was cleaned with a 70% ethanol solution. To be included in 
the test phase, rats they had to reach a minimum criterion on the training test (before 
treatment), which is 60 s maximum to step in the dark compartment of the maze. All the 
analyses were performed by the same observer, who was unaware of animal treatment. 
Sleeping Time.  
Sleeping parameters were determined in different groups of rats. To determine sleeping 
onset and recovery, immediately after anesthetic administration each rat was placed on 
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its back once every 30 s until it was unable to right itself within 30 s. Sleeping onset was 
defined as the interval between anesthetic injection and the time the rat was unable to 
turn itself upright at least twice within 1 min. Then each rat was left undisturbed on its 
back until it spontaneously regained its righting reflexes, defined as having at least three 
paws under its body. Complete recovery of the righting reflex was defined as the rat being 
able to turn itself upright. The time between loss and recovery of righting reflex for each 
rat was defined as sleeping time (cutoff180 min).28 All of the analyses were performed by 
the same observer, who was unaware of animal treatment. Endocannabinoid 
Measurement In accordance with Patel’s protocol in mice,7 rats were treated with 
propofol (300 mg/kg, intraperitoneally) or with its vehicle and killed 8 or 40 min after 
administration. Brain and plasma samples were subjected to a lipid extraction process, 
and the endocannabinoid content of the lipid extracts was determined using isotope-
dilution liquid chromatography-mass spectrometry as described previously.12 The brain 
tissue was collected and stored at 80°C. Before the extraction process, tissues were 
weighted and homogenized in polypropylene tubes (Sarstedt, Numbrecht, Germany) and 
kept in ice water. Five hundred µl of the described homogenized tissue solution was 
transferred to a 2-ml Eppendorf tube, and 20 µl of internal standard and 1 ml methyl 
tertiary butyl ether (Sigma-Aldrich, Italy) were added to extract the endocannabinoids. 
The mixture was vortexed for 1min and centrifuged at 12,000g for 6min. The clear 
supernatant was transferred into a clean 5-ml polypropylene tube (Sarstedt) and 
evaporated under vacuum at 37°C. The residue of all evaporated samples was 
reconstituted in 100 µl acetonitrile, vortexed for 30 s, and sonicated in 4°C water for 
15min. A 20 µl aliquot of the clear solution was used for liquid chromatography-tandem 
mass spectrometry analysis. All samples were injected in duplicates.  
Statistical Analysis  
The training and retention latencies of rats were analyzed with one-way ANOVA. Time-
dependent effects of propofol, the interactions between propofol and rimonabant, and 
propofol effects on endocannabinoid concentrations were analyzed with two-way 
ANOVAs. The source of the detected significances was determined by Tukey–Kramer post 
hoc tests. To determine whether learning had occurred, paired t-tests were used to 
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compare the training and retention latencies of the vehicle groups. Sleeping parameters 
were analyzed with Kruskal-Wallis one-way ANOVA on ranks or Mann–Whitney U test 
because of their non normal distribution. StatView software (SAS Institute, Cary, NC) was 
used to conduct statistical analyses. Normal data are expressed as mean ± SD; 
nonparametric data are expressed as median and percentiles. Two-tailed testing was used 
for all the analyses. P values of 0.05 were considered statistically significant. The number 
of rats per group is indicated in the figures and tables. 
Results 
Posttraining Administration of Propofol Enhances 48-h Inhibitory Avoidance Retention 
Performance 
This experiment examined whether immediate posttraining administration of propofol 
would enhance 48-h retention performance of inhibitory avoidance training. Average 
stepthrough latencies for all groups during training (i.e., before footshock and drug 
treatment) were 17.6±13.7 s (mean±SD). One-way ANOVA for training latencies revealed 
no significant differences between groups (F3,46=0.93, P=0.43). The 48-h retention 
latencies of rats given vehicle immediately after training were significantly longer than 
their entrance latencies during the training trial (t=5.59, P 0.0002), indicating that the rats 
retained memory of the shock experience. As shown in figure 1, propofol induced dose-
dependent retention enhancement. One-way ANOVA for 48-h retention latencies 
revealed a significant treatment effect (F3,43=7.82, P=0.0003). Post hoc analysis indicated 
that rats treated with the higher doses of propofol (300 or 350 mg/kg) had significantly 
longer retention than did those treated with vehicle or with 250 mg/kg propofol (P<0.01 
and P 0.05 for 300 and 350mg/kg, respectively). The lower dose of propofol (250 mg/kg), 
which did not induce anesthesia, did not induce retention enhancement. Three of 12 rats 
given 350 mg/kg propofol died of respiratory depression.  
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Fig. 1. Effects of posttraining administration of propofol on retention of an inhibitory avoidance 
response. Step-through latencies (mean±SD) on a 48-h retention test. Immediate posttraining 
administration of propofol (300 mg/kg) enhanced memory retention. Data are expressed as mean 
± SEM * P<0.05; ** P<0.01 versus vehicle; # P<0.05; ## P<0.01 versus 250 mg/kg propofol (n=12, 
vehicle; n=13, 250 and 300 mg/kg propofol; n=9, 350 mg/kg propofol). 
Propofol Administered Immediately or 30 min (but Not 90 or 180 min) after the Training 
Enhanced 48-h Inhibitory Avoidance Retention Performance 
To examine whether propofol influences the consolidation phase of memory processing, 
rats were treated with Propofol (300 mg/kg) immediately or 30, 90, or 180 min after 
training. Average step-through latencies for all groups during training, before foot shock 
and drug treatment, were 16.6 ± 13.0 s (mean ± SD). Two-way ANOVA for training 
latencies revealed no significant differences between groups (main effect of treatment 
F1,78=0.77, P=0.38; main effect of time of administration F3,78=2.0, P=0.12; interaction 
F3,78=1.54, P=0.21). Two-way ANOVA for 48-h retention latencies revealed a significant 
main effect of Propofol (F1,78=17.64, P=0.0001) as well as a significant main effect of time 
of administration (F3,78=3.76, P=0.014). Moreover, there was a statistically significant 
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interaction effect between treatment and time of administration (F3,78=4.76, P=0.0042). 
As shown in figure 2, post hoc analysis indicated that rats treated with propofol either 
immediately or 30 min after training had significantly longer retention latencies than did 
those given vehicle (P<0.01). Retention latencies of rats injected with propofol 
immediately or 30 min posttraining were significantly longer than were those of rats given 
propofol 180 min after the training (P<0.01).  
 
 
 
 
 
 
 
 
 
 
Fig. 2. 
Effects of immediate and delayed posttraining administration of propofol on retention of an 
inhibitory avoidance response. Step-through latencies (mean±SD) on a 48-h retention test. Rats 
injected with propofol immediately or 30 min posttraining showed retention latencies longer than 
those of rats injected with vehicle at the corresponding time point and with propofol 180 min after 
training. Data are expressed as mean ± SEM ** P<0.01 versus the corresponding vehicle group; ## 
P<0.01 versus rats injected with propofol 180 min after training (n=10, vehicle 30 min and 300 
mg/kg propofol 90 min; n=11, all other groups).  
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Posttraining Administration of Midazolam or Pentobarbital Does Not Enhance 48-h 
Inhibitory Avoidance Retention Performance 
To determine whether the propofol effect on inhibitory avoidance memory enhancement 
is specific for this anesthetic, rats were treated with anesthetic doses of midazolam (30, 
50, or 70mg/kg, intraperitoneally) or pentobarbital (60, 70, or 80 mg/kg, intraperitonelly) 
immediately after inhibitory avoidance training. For midazolam, average stepthrough 
latencies for all groups during training, before footshock and drug treatment, were 
17.7±13.9 s (mean±SD). One-way ANOVA for training latencies revealed no significant 
differences between groups (F3,34=0.17, P=0.92). As shown in figure 3A, one-way ANOVA 
for 48-h retention latencies indicated that midazolam did not significantly enhance 
retention latencies (F3,34=0.09, P=0.97). For pentobarbital, average step-through latencies 
for both groups during training, before foot shock and drug treatment, were 17.2±14.2 s 
(mean±SD). One-way ANOVA for training latencies revealed no significant differences 
between groups (F3,34=0.34, P=0.79). As shown in figure 3B, one-way ANOVA for 48-h 
retention latencies indicated that pentobarbital did not significantly enhance retention 
latencies (F3,34=0.21, P=0.89).  
 
Fig. 3. Effects of posttraining administration of midazolam or pentobarbital on retention of an 
inhibitory avoidance response. Step-through latencies (mean±SD) on a 48-h retention test. 
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Immediate posttraining administration of midazolam (A) or pentobarbital (B) did not enhance 
memory consolidation. Data are expressed as mean ± SEM. (n=9, 30 mg/kg midazolam and 70 or 
80 mg/kg pentobarbital; n=10 vehicle, 50 or 70 mg/kg midazolam and 60 mg/kg pentobarbital) 
The CB1 Antagonist Rimonabant Blocks the Memory-enhancing Effect Induced by 
Propofol 
This experiment examined whether the memory-enhancing effect of propofol depends on 
a concurrent activation of CB1 receptors. To address this issue, we investigated whether 
the CB1 receptor antagonist rimonabant (1 mg/kg) administered intraperitoneally 
immediately after inhibitory avoidance training would block the retention enhancement 
induced by propofol given 30 min later. Average step-through latencies for all groups 
during training, before foot shock and drug treatment, were 15.2±11.8 s. The 48-h 
retention latencies of rats given vehicle after training were significantly longer than their 
entrance latencies during the training trial (P=0.0001). As shown in figure 4, posttraining 
administration of rimonabant blocked the retention enhancement induced by propofol 
(300 mg/kg). Two-way ANOVA for 48-h retention latencies revealed a significant 
rimonabant plus propofol interaction effect (F1,27=11.70, P=0.002). Post hoc comparison 
revealed that retention latencies of rats given propofol alone were significantly longer 
than were those of vehicle-treated rats (P<0.01). Most importantly, retention latencies of 
rats given an otherwise non impairing dose of rimonabant together with propofol were 
significantly shorter than those of rats treated with propofol alone (P<0.01).  
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Fig. 4. Effects of the CB1 antagonist rimonabant on the memory-enhancing effects induced by 
propofol. Stepthrough latencies (mean±SD) on a 48-h retention test. Immediate posttraining 
administration of the cannabinoid receptor antagonist rimonabant (1 mg/kg) blocked the memory 
enhancing effects of propofol (300 mg/kg). Data are expressed as mean ± SEM. ** P<0.01 versus 
the corresponding vehicle group; ## P<0.01 versus the corresponding propofol group (n=7, 1 mg/kg 
rimonabant+vehicle propofol; n=8, all other groups) 
Sleeping Time 
Table 1 shows the effects of propofol, midazolam, and pentobarbital on sleeping 
parameters. Kruskal-Wallis ANOVA revealed no statistically significant effect on sleeping 
onset (H6=10.27, P=0.11). However, Kruskal-Wallis ANOVA revealed a statistically 
significant effect for sleeping time (H6=19.64, P=0.002). Post hoc comparisons (Mann–
Whitney U test with Bonferroni correction) revealed that rats given 50 mg/kg midazolam 
slept for a shorter amount of time than did rats given 70 or 80 mg/kg pentobarbital or 
those given 350 mg/kg propofol. None of the rats treated with the lower doses of 
midazolam (30 mg/kg) or propofol (250 mg/kg) lost righting reflex. Table 2 shows the 
effects of rimonabant on propofol in inducing anesthesia. Mann–Whitney U test showed 
no difference between rats pretreated with rimonabant compared with rats pretreated 
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with vehicle on sleeping onset or time induced by propofol (U=5.0, P=0.11; U=11.000, 
P=0.75, respectively), indicating that the anesthetic effect of propofol is independent from 
the indirect activation of the endocannabinoid system.  
 
*P<0.05 vs. 350 mg/kg propofol and 70 or 80 mg/kg pentobarbital. 
 
 
 
Endocannabinoid Measurement 
Two-way ANOVA for propofol effects on Endocannabinoid content revealed a statistically 
significant interaction between treatment and time of administration (F1,19=7.1, P=0.015). 
Post hoc comparisons revealed that Propofol increases anandamide concentrations in rat 
brains 8 min after administration (P< 0.05, table 3).  
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* P<0.05 versus vehicle-treated rats (8 min). 
Discussion 
The current findings indicate that propofol, at anesthetic doses, enhances memory 
consolidation of inhibitory avoidance training in rats when administered immediately 
after the training experience. This memory enhancement is blocked by coadministration 
of the CB1 cannabinoid receptor antagonist rimonabant, suggesting that the enhancing 
effect of propofol on memory consolidation depends on an indirect activation of CB1 
receptors. In contrast, midazolam and pentobarbital, two anesthetics that do not increase 
endocannabinoid signaling,7did not enhance the consolidation of memory of inhibitory 
avoidance training. The current findings may appear at odds with preclinical and clinical 
findings indicating that propofol induces amnesia. For example, Veselis et al. 5 reported 
that propofol inhibits conscious memory processes in human subjects soon after memory 
encoding and that it impairs the acquisition or encoding of material into long-term 
memory. In addition, propofol has been reported to induce amnesia of training in rats on 
the same inhibitory avoidance task used in the current study.6 However, a critical 
difference between these investigations and the current study is that in the human 
studies, memory function was assessed shortly after drug administration, whereas in the 
preclinical study, rats were given the drug before training. Therefore, acute 
pharmacologic effects could have influenced directly both the acquisition and retention of 
the training. In contrast, in our study the drug was administered after the training and was 
not present during the acquisition phase. Thus, the enhancing effects of propofol on 
retention performance in our study are likely mediated by specific influences on the 
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consolidation of memory of the training experience.29 The use of posttraining drug 
manipulation is a widely accepted method for effectively dissociating memory processes 
from secondary behavioral effects of non-associative nature, such as those related to 
sensory sensitivity.30 Because retention testing took place 48 h after training and drug 
treatment, these findings further exclude residual pharmacologic effects as having a direct 
influence on behavior during retention testing. Moreover, the effect of post-training 
propofol administration on retention enhancement was time dependent: propofol 
administration immediately or 30 min after inhibitory avoidance training resulted in 
memory enhancement, whereas administration of Propofol 90 or 180 min after training 
was ineffective. Together these findings provide evidence that propofol enhances time-de 
pendent processes underlying the consolidation of memory for emotionally arousing 
experiences. The posttraining drug administration protocol used in the current article has 
a translational value to humans. Acute sedation or even the induction of anesthesia 
immediately after a traumatic experience (e.g., in the consolidation phase of a traumatic 
memory) is a common clinical scenario in emergency medicine and in the ICU. Our 
findings demonstrate that propofol is able to enhance memory consolidation when 
administered immediately after the exposure to a traumatic event and that this effect on 
memory depends on an indirect activation of the endocannabinoid system. In accordance 
with the behavioral data, we also found that propofol administration increases 
anandamide concentrations in the rat brain 8 min after injection, whereas anandamide 
plasma concentrations remain unaffected. Our data are in accordance with preclinical and 
clinical evidence. Patel et al.7 demonstrated increased concentrations of anandamide in 
the mouse brain after systemic administration of propofol in contrast to the 
administration of benzodiazepines, barbiturates, or volatile anesthetics; the effect of 
propofol on anandamide concentrations is mediated by an inhibition of fatty acid amide 
hydrolase, the major degradation enzyme of anandamide.7 In humans undergoing general 
anesthesia, plasma concentrations of the endocannabinoid anandamide remained 
unchanged during Propofol anesthesia but were significantly reduced during anesthesia 
with volatile agents.12,13 The basolateral complex of the amygdala (BLA) appears to be a 
critical site for mediating drug effects on memory performance, including those of 
 Chapter 1 
  
 
28 
propofol. One study reported that permanent neurotoxic lesions of the BLA produced 
with N-methyl-D-aspartate blocked the amnestic effect of pretraining propofol 
administration of rats trained on an inhibitory avoidance task.6 We recently have shown 
that the endocannabinoid system in the BLA is involved in the enhanced consolidation of 
inhibitory avoidance memory and that CB1 activity within the BLA is essential for 
mediating glucocorticoid effects on long-term memory.23–31 Based on these findings, a 
newmodel has emerged.32–33In this model, stress-induced glucocorticoids bind to 
membrane-bound receptors in the BLA that activate a G-protein signaling cascade that 
induces endocannabinoid synthesis. The ensuing release of endocannabinoid ligands 
could diffuse to local -aminobutyric acid–mediated (GABAergic) terminals and inhibit -
aminobutyric acid release onto noradrenergic terminals in the BLA. The end result of this 
process is an increased norepinephrine release within the BLA and subsequently an 
enhancement of emotional memory consolidation. Many sedative and anamnestic effects 
of general anesthetics, including those of propofol, crucially depend on -aminobutyric acid 
release. The current findings demonstrate that the enhancing effects of propofol 
onmemory consolidation depend on concomitant CB1 receptor activity, so we 
hypothesize that the anamnestic effects of propofol are mediated by an 
endocannabinoid-induced inhibition of γ-aminobutyric acid release, resulting in a more 
pronounced memory consolidation during stressful conditions when glucocorticoid 
signaling is high.34  The pharmacokinetic properties of midazolam, pentobarbital, and 
propofol differ to a large extent, but all three drugs share the pharmacodynamic 
capability to potentiate -aminobutyric acid neurotransmission.35 Our results showing that 
rats treated with midazolam (50 mg/kg) slept less than did rats treated with propofol (350 
mg/kg) or pentobarbital (70 or 80 mg/kg) are in accordance with clinical evidence showing 
that midazolam has a shorter half-life than Propofol and barbiturates.35  However, neither 
rats treated with the higher dose of midazolam nor the ones treated with pentobarbital 
showed differences in the sleeping parameters compared with those treated with 
propofol. Although Propofol enhances memory consolidation through an activation of the 
endocannabinoid system, the anesthetic effect of Propofol does not depend on this 
activation. The CB1 receptor antagonist rimonabant blocks the propofol-enhancing effect 
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on memory consolidation but does not influence propofol’s effects on sleeping. On the 
whole, these data suggest that, unlike midazolam and pentobarbital, propofol induces 
selective effects on memory consolidation, which are linked to the activation of the 
endocannabinoid system and not related to the potentiation of GABAergic 
neurotransmission. These findings, together with the results showing that midazolam and 
pentobarbital, at anesthetic doses, did not influence memory consolidation strongly 
corroborate the hypothesis that propofol’s effects on memory consolidation are not 
attributable to a general nonspecific anesthetic effect. In summary, our study 
demonstrates that propofol enhances memory consolidation via an endocannabinoid-
mediated mechanism. These effects are markedly different from those of other direct 
GABAergic agents such as midazolam or pentobarbital. These findings from animal 
experiments suggest that propofol should be used with caution in individuals during the 
aftermath of an acute traumatic event and may help to explain the increased incidence of 
aversive memories from intraoperative awareness seen in patients undergoing total 
intravenous anesthesia with propofol.36 Likewise, the findings suggest that pharmacologic 
manipulation of endocannabinoid signaling could be a useful intervention aimed at 
blocking memory consolidation immediately after a traumatic event.  
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Abstract 
Cannabinoid compounds may influence both emotional and cognitive processes 
depending on the level of environmental aversiveness at the time of drug administration. 
However, the mechanisms responsible for these responses remain to be elucidated. The 
present experiments investigated the effects induced by the endocannabinoid transport 
inhibitor AM404 (0.5-5 mg/kg, i.p.) on both emotional and cognitive performances of rats 
tested in a Spatial Open Field task and subjected to different experimental settings, 
named High Arousal and Low Arousal conditions.  
The two different experimental conditions influenced emotional reactivity independently 
of drug administration. Indeed, vehicle-treated rats exposed to the Low Arousal condition 
spent more time in the centre of the arena than vehicle-treated rats exposed to the High 
Arousal context. Conversely, the different arousal conditions did not affect the cognitive 
performances of vehicle-treated animals such as the capability to discriminate a spatial 
displacement of the objects or an object substitution. 
AM404 administration did not alter locomotor activity of the animals exposed to both 
environmental conditions. Interestingly, AM404 administration increased the emotional 
reactivity of rats exposed to the High Arousal condition but did not influence emotionality 
of rats exposed to the Low Arousal condition. Moreover, AM404 administration 
influenced the cognitive parameters depending on the level of emotional arousal: it 
impaired the capability of rats exposed to the High Arousal condition to recognize a novel 
object while it did not induce any impairing effect in rats exposed to the Low Arousal 
condition. 
These findings suggest that drugs that enhance endocannabinoid signalling induce 
different effects on recognition memory performance depending on the level of 
emotional arousal induced by the environmental conditions. 
 
Keyword: Cannabinoid system, endocannabinoids, AM404, emotionality, short-term 
memory, cognition. 
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Introduction 
The endocannabinoid system is a crucial regulator of central nervous system (CNS) 
function (Cravatt et al., 1996; Di Marzo and Matias, 2005; Pacher et al., 2006; Trezza et al., 
2008b; Campolongo et al., 2009b,c, 2011; Bisogno and Di Marzo, 2010; Hill and McEwen, 
2010). Endocannabinoids are released from post-synaptic neurons in an activity-
dependent manner, travel retrogradely through the synaptic cleft and activate 
presynaptic cannabinoid type 1 receptors (CB1), thus suppressing neurotransmitter 
release from axon terminals (Wilson and Nicoll, 2002). Among the endogenous 
cannabimimetic signaling molecules, anandamide (N-arachidonoylethanolamine, AEA) 
and 2-arachidonoylglycerol (2-AG) stand out as the ﬁrst identiﬁed and most intensively 
studied (Ueda et al., 1995, 2011; Di Marzo, 1998; Piomelli, 2003; Waku, 2006). Receptor 
activation by endocannabinoids ends by the removal from the synaptic cleft operated by a 
transport system present in neural and non-neural cells (Di Marzo et al., 1994; Beltramo 
et al., 1997; Hillard et al., 1997) followed by hydrolysis operated by fatty-acid amide 
hydrolase (FAAH, that hydrolyzes anandamide) or monoacylglycerol lipase (MAGL, that 
cleaves 2-AG) (Desarnaud et al., 1995; Hillard et al., 1995; Ueda et al., 1995; Cravatt et al., 
1996). Interestingly, while the endocannabinoid hydrolyzing enzymes have been fully 
identiﬁed and cloned, the functional properties of the putative transporter have been 
only partially characterized (Hillard and Jarrahian, 2003; Yates and Barker, 2009; Fu et al., 
2011) and its molecular identity remains still unknown. CB1 receptor is crucially involved 
in neural plasticity mechanisms related to the processing, consolidation, and extinction of 
emotionally salient cognitive events (Marsicano et al., 2002; Laviolette and Grace, 
2006a,b; Campolongo et al., 2009a,b; Mackowiak et al., 2009; Abush and Akirav, 2010; 
Akirav, 2011; Hauer et al., 2011). This ﬁts well with the notion that CB1 receptors are 
highly expressed in brain structures including the basolateral amygdala (BLA), the medial 
prefrontal cortex (mPFC) and the hippocampus (Breivogel and Childers, 1998; Mackie, 
2005; Katona, 2009), strictly associated with both cognitive and emotional processes 
(Laviolette and Grace, 2006a; Viveros et al., 2007; McLaughlin and Gobbi, 2011; Tan et al., 
2011).  
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Animal studies have demonstrated that the endocannabinoid system modulates 
recognition memory by altering the mechanisms responsible for this process within the 
hippocampus and selectively affecting the encoding stage (Barna et al., 2007). Moreover, 
the important involvement of other structures, for instance the amygdala, in the 
modulation of memory consolidation and extinction for emotional events has been ﬁrmly 
established (McGaugh, 2000; Vianna et al., 2004; Clarke et al., 2008; de Oliveira Alvares et 
al., 2008, 2010; Campolongo et al., 2009b; Ganon-Elazar and Akirav, 2009;Manwell et al., 
2009; Roozendaal and McGaugh, 2011). In line with the widespread distribution of CB1 
receptors throughout the limbic system, it has been extensively demonstrated that 
cannabinoid compounds also induce diverse effects on anxiety- and fear-related 
behaviors (Trezza et al., 2008a, 2012; Micale et al., 2009; Moreira and Wotjak, 2010; 
Terzian et al., 2011). Interestingly, cannabinoid effects on emotionality are biphasic, as it 
is also reported by cannabis abusers (Fant et al., 1998;Hall and Solowij, 1998; Bolla et al., 
2002; Curran et al., 2002). The classical explanation to this phenomenon is often provided 
by the use of different doses of cannabinoid drugs, with low doses generally inducing 
anxiolytic-like effects and high doses often causing the opposite. A new and appealing 
explanation to this phenomenon is now emerging, underlying that these opposite effects 
may also depend on previous experiences, the context of use and the level of emotional 
arousal at the time of drug administration/consumption (Akirav, 2011; Sciolino et al., 
2011). Drugs that interfere with endocannabinoid degradation increase ongoing 
endocannabinoid signaling in a temporarily and spatially restricted manner (Janero et al., 
2009). However, preclinical evidence has shown that indirect cannabinoid agonists can 
also induce biphasic effects on behavior, depending on the emotional state of the subject. 
For instance, it has been recently demonstrated that the FAAH inhibitor URB597 does not 
affect anxiety under mildly stressful circumstances but has robust anxiolytic-like effects in 
highly aversive testing conditions (Haller et al., 2009). These ﬁnding leaves open the 
possibility thatinhibitors of endocannabinoid transport, which prolong endocannabinoid 
actions by preventing endocannabinoid access to intracellular hydrolyzing enzymes 
(Beltramo et al., 1997; Kathuria et al., 2003), may inﬂuence both emotional and cognitive 
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processes depending on the level of environmental aversiveness at the time of drug 
administration.  
To address this issue, in the present study we investigated the effect of the prototypical 
endocannabinoid transport inhibitor, AM404 in a non-aversive task, the Spatial Open Field 
test under two experimental conditions differing by the level of emotional arousal at the 
time of testing. The Spatial Open Field task has been extensively used (Poucet et al., 1986; 
Thinus-Blanc et al., 1987; Poucet, 1989, 1993; Ricceri et al., 1999, 2002; Scattoni et al., 
2004; de Bartolo et al., 2010) and permits to assess both emotional and cognitive 
parameters, in terms of reactivity to a spatial or an object novelty, by exploiting the 
natural propensity of rodents to explore the environment. The High Arousal condition 
(HA) was obtained by testing rats in an empty arena under white light illumination 
without previous handling, while the Low Arousal emotional processes (Laviolette and 
Grace, 2006a; Viveros et al., 2007; McLaughlin and Gobbi, 2011; Tan et al., 2011).  
Animal studies have demonstrated that the Endocannabinoid system modulates 
recognition memory by altering the mechanisms responsible for this process within the 
hippocampus and selectively affecting the encoding stage (Barna et al., 2007). Moreover, 
the important involvement of other structures, for instance the amygdala, in the 
modulation of memory consolidation and extinction for emotional events has been ﬁrmly 
established (McGaugh, 2000; Vianna et al., 2004; Clarke et al., 2008; de Oliveira Alvares et 
al., 2008, 2010; Campolongo et al., 2009b; Ganon-Elazar and Akirav, 2009;Manwell et al., 
2009; Roozendaal and McGaugh, 2011). In line with the widespread distribution of CB1 
receptors throughout the limbic system, it has been extensively demonstrated that 
cannabinoid compounds also induce diverse effects on anxiety- and fear-related 
behaviors (Trezza et al., 2008a, 2012; Micale et al., 2009; Moreira and Wotjak, 2010; 
Terzian et al., 2011). Interestingly, cannabinoid effects on emotionality are biphasic, as it 
is also reported by cannabis abusers (Fant et al., 1998;Hall and Solowij, 1998; Bolla et al., 
2002; Curran et al., 2002). The classical explanation to this phenomenon is often provided 
by the use of different doses of cannabinoid drugs, with low doses generally inducing 
anxiolytic-like effects and high doses often causing the opposite. A new and appealing 
explanation to this phenomenon is now emerging, underlying that these opposite effects 
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may also depend on previous experiences, the context of use and the level of emotional 
arousal at the time of drug administration/consumption (Akirav, 2011; Sciolino et al., 
2011). Drugs that interfere with endocannabinoid degradation increase ongoing 
endocannabinoid signaling in a temporarily and spatially restricted manner (Janero et al., 
2009). However, preclinical evidence has shown that indirect cannabinoid agonists can 
also induce biphasic effects on behavior, depending on the emotional state of the subject. 
For instance, it has been recently demonstrated that the FAAH inhibitor URB597 does not 
affect anxiety under mildly stressful circumstances but has robust anxiolytic-like effects in 
highly aversive testing conditions (Haller et al., 2009). This ﬁnding leaves open the 
possibility that inhibitors of endocannabinoid transport, which prolong endocannabinoid 
actions by preventing endocannabinoid access to intracellular hydrolyzing enzymes 
(Beltramo et al., 1997; Kathuria et al., 2003), may inﬂuence both emotional and cognitive 
processes depending on the level of environmental aversiveness at the time of drug 
administration.  
To address this issue, in the present study we investigated the effect of the prototypical 
endocannabinoid transport inhibitor, AM404 in a non-aversive task, the Spatial Open Field 
test under two experimental conditions differing by the level of emotional arousal at the 
time of testing. The Spatial Open Field task has been extensively used (Poucet et al., 1986; 
Thinus-Blanc et al., 1987; Poucet, 1989, 1993; Ricceri et al., 1999, 2002; Scattoni et al., 
2004; de Bartolo et al., 2010) and permits to assess both emotional and cognitive 
parameters, in terms of reactivity to a spatial or an object novelty, by exploiting the 
natural propensity of rodents to explore the environment. The High Arousal condition 
(HA) was obtained by testing rats in an empty arena under white light illumination 
without previous handling, while the Low Arousal condition (LA) was obtained by 
extensively handling the animals before testing in an arena with the ground loaded with 
familiar bedding, under a dim red lighted room. By manipulating the experimental 
conditions and the tone of endogenous cannabinoids, this study may help to explain how 
the interaction between endocannabinoids and environment could inﬂuence recognition 
memory in rats. 
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Materials and Methods 
Animals 
Male adult Wistar rats (300 g at the time of testing, Charles River Laboratories, Italy) were 
housed in groups and maintained in a temperature-controlled environment (20 ± 1°C) 
under a 12-h light/12-h dark cycle (7:00 am to 7:00 pm lights on) with unlimited access to 
food and water. All procedures involving animal care or treatments were approved by the 
Italian Ministry of Health and performed in compliance with the guidelines of the US 
National Institutes of Health (NIH) and the Italian Ministry of Health (D.L. 116/92), the 
Declaration of Helsinki, the Guide for the Care and Use of Mammals in Neuroscience and 
Behavioral Research (National Research Council 2004) and the Directive 2010/63/EU of 
the European Parliament and of the Council of 22 September 2010 on the protection of 
animals used for scientific purposes. 
Drug Treatments  
N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (AM404, 0.5-1-5 mg/kg), 
purchased from Tocris Bioscience (UK), was dissolved in a vehicle containing 10% 
polyethylene glycol, 10% Tween-80 and 80% saline. Drug solutions were freshly prepared 
before each experiment and administered by intraperitoneal injection in a volume of 1 
ml/kg 15 minutes before the beginning of the task. 
Spatial Open Field procedures 
The apparatus consisted in an open-field arena made of black Plexiglas (80 x 80 x 60 cm) 
surrounded with a visually uniform environment. A video camera above the field was 
connected to a video recorder. Experiments were performed between 10.00 am and 2.00 
pm. The test schedule consisted of six 5-min sessions, separated by 3-min delays during 
which the subjects were returned to their home cage (fig.1). During session 1, each rat 
was placed into the centre of the empty arena to allow it to become familiar with the 
apparatus and to record baseline levels of locomotor and exploratory activity. Starting 
from session 2, three different objects were simultaneously present in the open field: 
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Object A, a dark metal parallelepiped (4 cm high x 13 cm wide x 9 cm long); Object B, a 
transparent Plexiglas cube with holes regularly distributed on the sides (height = 10 cm); 
Object C, a grey plastic square (10 x 10x 10 cm) with a central triangle forming a 90° 
angle. During sessions 2-3, the A, B and C objects were placed in the arena. In session 4, 
the spatial test session, the configuration was changed by moving two objects: object B 
replaced object A which was itself displaced at the periphery of the apparatus. In session 
5, the configuration of the objects was unchanged to let the rats habituate to the new 
arrangement of the objects. In the last session (session 6) one of the familiar, non-
displaced objects (object C) was replaced by a new object (object D, which consisted of a 
black-and-white plastic cylinder, height = 13 cm; diameter = 6 cm (fig. 1).  
We exposed the rats to two experimental conditions, named High Arousal (HA) and Low 
Arousal (LA) conditions. In the HA condition (experiment 1), the test was performed 
under normal light (30-40 lux), rats were not handled and tested in an empty arena (no 
bedding). In the LA condition (experiment 2), the test was performed under dim red light 
(2 lux) condition, rats were extensively habituated to the experimenter and to the 
injection procedure for 1 week before the experiment (every day, 1 min per each rat) and 
tested in an arena with the ground loaded with familiar bedding.  
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FIGURE 1 Spatial Open-Field procedure. Schematic diagram representing the object conﬁguration 
in the Spatial Open-Field test: (A) session 1, open ﬁeld without objects; (B) session 2, habituation 
session with three stable objects; (C) sessions 3–4, spatial change discrimination sessions where 
object B displaced object A (session 4); (D) session 5–6, object novelty sessions where object D 
replaced object C (session 6). 
Statistical Analysis 
Data collection was performed from the same observer who was unaware of animal 
treatment using the Observer XT software (Noldus, the Netherland). During the first 
session, frequency and/or duration of the following responses were measured: crossings, 
rearings and time spent in the centre of the apparatus. From sessions 2 to 6, object 
exploration was measured as total time spent by the animal in contact with an object (1 
sec as minimal contact was considered) throughout all sessions 2-6.  
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The total time spent by rats investigating all objects throughout all sessions has been 
considered as an indicator of general investigative activity. A contact was defined as the 
subject's snout actually touching an object. In session 4, the spatial arrangement of the 
objects was modified and response to spatial change was assessed by comparing the 
mean time spent in contact with both Displaced (DO) and Non-Displaced (NDO) Objects in 
session 4 minus the mean time spent in contact with the same object in session 3. A 
discrimination index of the response to the spatial change was obtained by subtracting 
the NDO value to DO value. Finally, the response to the non-spatial novelty was assessed 
by comparing mean time in contact with the Substituted Object (SO, unfamiliar) and Non-
Substituted Objects (NSO, familiar) in session 6 minus the mean time spent with objects 
located in the corresponding position in session 5. A discrimination index of the response 
to the non-spatial novelty was obtained by subtracting the NSO value to SO value. 
Unpaired t-test was used to compare the behavioural performance of vehicle groups. 
One-sample t tests were used to determine whether the discrimination index was 
different from zero. A probability level of <0.05 was accepted as statistically significant. 
Results 
Different arousal conditions influenced emotional behaviour and object exploration but 
did not alter cognitive performances of vehicle-treated animals 
Unpaired t-test showed that the different arousal context did not affect the locomotor 
activity of the vehicle groups. Both crossing (fig. 2A) and rearing (fig. 2B) frequencies did 
not statistically differ between the two groups (t=-0.66; p=0.52; t=1.09; p=0.29). 
However, unpaired t-test showed that the different arousal conditions influenced the 
emotional behaviour of vehicle-treated animals exposed to the different experimental 
contexts. Rats treated with vehicle and exposed to a High Arousal condition (HA group) 
spent less time in the centre of the arena than vehicle-treated rats exposed to a Low 
Arousal context (LA group) (t=-4.11; p=0.0005, fig. 2C).  
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FIGURE 2 Effects induced by different arousal conditions on locomotor activity and emotional 
behavior of vehicle-treated rats. Locomotor activity: number of crossing (A) and rearing (B) in 
session 1. Emotional behavior: time spent in the center of the arena in session 1 (C). **P < 0.01. 
Data are expressed as mean ± SEM. (High Arousal: HA n = 10; Low Arousal: LA n = 15) 
Unpaired t-test showed that rats treated with vehicle and exposed to a HA context spent 
less time investigating objects than vehicle-treated rats exposed to a LA context (t=-4.41; 
p<0.0001, fig. 3A). Additionally, unpaired t-test showed that both vehicle groups did not 
differ in the discrimination index for a spatial object displacement in session 4 (t=0.60; 
p=0.55, fig. 3B) and for the substitution of the objects in session 6 (t=0.47; p=0.64, fig. 
3C). However, One-sample t tests revealed that while both vehicle groups were able to 
discriminate the object novelty (veh-HA, t=4.49, P=0.0015; veh-LA, t14=2.61, P=0.02, fig. 
3C) they did not respond to a spatial rearrangement (veh-HA, t=1.10, P=0.30; veh-LA, 
t=0.16, P=0.88, fig. 3B). 
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FIGURE 3 Effects induced by different arousal conditions on object investigation and cognitive 
performances of vehicle-treated rats. Total investigation time of all objects through sessions (A) 
spatial change discrimination (B) and object novelty discrimination (C).**P < 0.01. Data are 
expressed as mean ± SEM. (High Arousal: HA n = 10; Low Arousal: LA n = 15) 
AM404 administration did not alter locomotor activity and emotional behaviour in rats 
exposed to different arousal conditions 
AM404 administration did not alter the locomotor activity of rats exposed to either a HA 
or LA condition. One–way ANOVA for crossing (fig. 4A) and rearing (fig. 4B) frequencies in 
session 1 for AM404-treated rats exposed to a HA condition did not show a statistically 
significant difference (F3,36=0.60; p=0.62; F3,36=1.44; p=0.25, respectively). Moreover, one–
way ANOVA for the number of crossings (fig. 4C) or rearings (fig. 4D) in session 1 did not 
show a statistically significant difference between vehicle- and AM404-treated rats 
exposed to a LA condition (F3,50=0.97; p=0.42; F3,50=2.21; p=0.10, respectively). AM404 
administration did not affect the emotional reactivity in rats exposed to either a HA or LA 
condition. Indeed, one-way ANOVA showed that vehicle- and AM404-treated rats did not 
differ  for the time spent in the centre of the arena in session 1 (HA condition: F3,36=1.25; 
p=0.31; fig. 5A; LA condition: F3,50=1.18; p=0.33; fig. 5B).  
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FIGURE 4 Effects of AM404 administration on locomotor activity in rats exposed to high arousal 
(HA) or low arousal (LA) conditions. Number of crossing (A) and rearing (B) of rats exposed to HA 
or LA conditions (C, D, respectively) in session 1. Data are expressed as mean ± SEM. (HA: veh n = 
10, 0.5mg/kg n = 11, 1 mg/kg n = 10, 5 mg/kg n = 9;LA: veh n = 15, 0.5mg/kg n = 12, 1 mg/kg n = 
14, 5 mg/kg n = 13). 
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FIGURE 5 Effects of AM404 administration on emotional behavior in rats exposed to high arousal 
(HA) or low arousal (LA) conditions. Time spent in the center of the arena by rats exposed to HA (A) 
or LA conditions (B) in session 1. Data are expressed as mean ± SEM.(HA:veh n = 10, 0.5mg/kg n = 
11, 1 mg/kg n = 10, 5 mg/kg n = 9; LA: veh n = 15, 0.5mg/kg n = 12, 1 mg/kg n = 14, 5 mg/kg n = 
13). 
AM404 administration influenced object exploration depending on the different arousal 
condition 
One–way ANOVA showed that administration of AM404 influenced the object 
investigation measured over all sessions in rats exposed to a HA context (F3,193=2.62; 
p=0.05). Post-hoc analysis revealed that rats treated with a lower dose of the indirect 
agonist spent less time investigating the objects compared to their respective vehicle 
group (p<0.05, fig. 6A). On the other hand, one –way ANOVA revealed that AM404-
treated rats exposed to a LA context spent the same amount of time investigating the 
objects as the vehicle-treated animals (F3,265=0.54; p=0.66; fig. 6B). 
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FIGURE 6 Effects of AM404 administration on object investigation in rats exposed to high arousal 
(HA) or low arousal (LA) conditions. Total investigation time of all objects by rats exposed to HA (A) 
or LA (B) conditions through sessions 2–6. *P < 0.05. Data are expressed as mean ± SEM. (HA: veh 
n = 10, 0.5mg/kg n = 11, 1 mg/kg n = 10, 5 mg/kg n = 9; LA: veh n = 15, 0.5mg/kg n = 12, 1 mg/kg n 
= 14, 5 mg/kg n = 13). 
AM404 administration did not influence spatial change discrimination while it altered 
object novelty recognition in rats exposed to different arousal conditions. 
One–way ANOVA showed that administration of AM404 did not influence the rat 
capability to discriminate the object displacement under both the HA (fig. 7A) or LA 
(fig.7B) experimental conditions (F3,36=1.176; p=0.34; F3,50=2.24; p=0.095, respectively). 
However, one–way ANOVA showed a statistical significant effect on the capability of the 
rats to discriminate a novel object under a HA condition (F3,36=4.32; p=0.01; fig. 8A). Post-
hoc comparisons revealed that rats administered with AM404 0.5 and 1 mg/kg were not 
able to discriminate the new object as vehicle-treated rats did (p<0.05). One–way ANOVA 
revealed that AM404 administration to LA exposed rats did not influence the capability of 
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the rats to discriminate the new object compared to the vehicle group (F3,50=0.26; p=0.85; 
fig. 8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 Effects of AM404 administration on spatial change discrimination in rats exposed to high 
arousal (HA) or low arousal (LA conditions. Spatial change discrimination index of rats exposed to 
HA (A) or LA (B) conditions. Tim spent in contact with Displaced (DO) and Non-Displaced (NDO) 
Objects in session 4 minus the mean time spent in contact with the same object in session 3. A 
discrimination index was obtained by subtracting the NDO value to DO value. Data are expressed 
as mean ± SEM.(HA:veh n = 10, 0.5mg/kg n = 11, 1 mg/kg n = 10, 5 mg/kg n = 9; LA: veh n = 15, 
0.5mg/kg n = 12, 1 mg/kg n = 14, 5 mg/kg n = 13). 
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FIGURE 8 Effects of AM404 administration on object novelty discrimination in rats exposed to high 
arousal (HA) or low arousal (LA) conditions. Object novelty discrimination index of rats exposed to 
HA (A) or LA (B) conditions. Time spent in contact with Substituted Object (SO, unfamiliar) and 
Non-Substituted Objects (NSO, familiar) in session 6 minus the mean time spent with objects 
located in the corresponding position in session 5. A discrimination index was obtained by 
subtracting the NSO valuetoSOvalue.*P < 0.05. Data are expressed as mean ± SEM. (HA: veh n = 10, 
0.5mg/kg n = 11, 1 mg/kg n = 10, 5 mg/kg n = 9; LA: veh n = 15, 0.5mg/kg n = 12, 1 mg/kg n = 14, 5 
mg/kg n = 13 
 
Discussion 
The present ﬁndings demonstrate that: (1) different levels of environmental aversiveness 
strongly inﬂuence the emotional reactivity of untreated rats without affecting the 
cognitive performance in the Spatial Open-Field test; (2) endocannabinoids affect 
recognition memory of rats in the Spatial Open Field test depending on the level of 
emotional arousal induced by the environmental conditions. The Spatial Open-Field is a 
non-aversive test that permits to assess several behaviors which are indicative of the 
emotional state of the animal as well as the reactivity to both spatial rearrangement 
(spatial novelty) or the replacement of one familiar object with a new one (object novelty, 
as in the classical object recognition task) (Poucet et al., 1986; Thinus-Blanc et al., 1996). 
This test exploits the natural propensity of rodents to explore the environment without 
using rewards or punishments.  
Previous studies have shown that naive rodents respond to a new spatial displacement or 
substitution by renewed exploration of the entire environment and/or by selective 
reinvestigation of the displaced/substituted objects (Poucet et al., 1986; Thinus-Blanc et 
al., 1987; Poucet, 1989, 1993; Ricceri et al., 1999, 2000, 2002; Scattoni et al., 2004; de 
Bartolo et al., 2010). The one-day six-session assessment of the task used in our study 
permits to determine pharmacological effects on short-term memory as well as on 
emotional reactivity of the subject. Activation of emotional responses, triggered by 
stressful stimuli, is crucial in the modulation of contextual learning and memory 
 Chapter 2 
  
 
51 
performances (McGaugh and Roozendaal, 2002; McGaugh, 2004; Morris, 2006; 
Campolongo et al., 2009b; Hill et al., 2010). There is evidence that behavioral responses to 
the environmental stimuli are strictly dependent on the emotional reactivity induced by 
the environment itself (Blanchard et al., 2001; Haller et al., 2009). The environmental–
induced arousal is critically involved in assessing the novelty and salience of the external 
stimuli in terms of relevance for the adaptation and survival (Poucet, 1993; Biegler and 
Morris, 1996; Breivogel and Childers, 1998). Thus, when compared with a previous 
experience, a novel information recognized as highly relevant is committed to and stored 
by the memory (Lemaire et al., 1999). However, the mechanisms underlying 
themodulation of responsiveness to the environment and its evaluation in evolutionary 
terms both under LA or HA contexts remain to be elucidated. Based on previous ﬁndings 
(Szeligo and Leblond, 1977; Sahakian et al., 1982; Morato and Castrechini, 1989; Griebel 
et al., 1993; Escorihuela et al., 1994; Hall et al., 1998; Varty et al., 2000; Haller et al., 
2009), in order to characterize the behavioral responses to different environmental 
situations, we manipulated the experimental context to create two opposite arousal 
conditions by using two different protocols: (1) rats either extensively handled or not 
handled by the experimenter before testing, (2) isolated- or grouped-housed rats; (3) 
bright or dim red light conditions; (4) without or with familiar bedding during the testing 
phase for HA or LA conditions, respectively (for a comprehensive description see 
Materials and Methods). By using these different experimental conditions, we were able 
to induce a high or a low state in the animal, independently of any drug administration. 
To ﬁrst characterize the behavioral responses of rats to different environmental situations 
in the Spatial Open Field task, regardless of any drug administration, we analyzed the 
performance of vehicle-treated rats exposed to a HA or a LA context. The analysis of the 
ﬁrst session of the Spatial Open Field task (when no objects were present) showed that 
locomotor activity was not inﬂuenced by the two different arousal conditions, while the 
different environmental situations inﬂuenced the level of emotional reactivity of the 
animals. Vehicle-treated rats, exposed to the LA context, spent indeed more time in the 
center of the open ﬁeld than vehicle-treated rats exposed to the HA context. This result 
indicates that the LA environment may induce a lower level of emotional activation (Prut 
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and Belzung, 2003). The view that LA condition induces a lower level of emotional 
activation is also supported by behavioral analysis derived from sessions 2 to 6 of the task, 
in which the rats encountered different objects, also located in different positions in the 
open-ﬁeld arena. Rats exposed to the LA context spent more time investigating the 
objects than rats exposed to the HA context, suggesting that a lower state of anxiety 
urges animals to better explore the objects (Crawley, 1985). Concerning the cognitive 
performance, the different level of emotional activation derived by exposure to the two 
environmental conditions did not inﬂuence the cognitive parameters measured in the 
task. Indeed, vehicle-treated rats exposed to either HA or LA conditions were equally able 
to recognize the object substitution but failed to respond to the object displacement. 
Interestingly, Ricceri and co-workers (Ricceri et al., 2000) showed that only 90-day-old 
mice were able to discriminate a spatial object rearrangement, while 46-day-old mice 
were not. In our study, we used young adult rats; this leaves open the possibility that the 
ability to discriminate a spatial change has to be still developed by rats at this age. 
Moreover, our ﬁndings are in accordance with the general assumption that the capability 
to recognize a new setting of the environment is important for the species survival, but 
the impact of the object novelty is more salient than a spatial rearrangement with the 
same objects (Mumby et al., 2002).  
Extensive evidence demonstrates that the Endocannabinoid system is a crucial regulator 
of emotionality and cognition (Marsicano et al., 2002; Laviolette and Grace, 2006a,b; 
Campolongo et al., 2009a,b; Mackowiak et al., 2009; Abush and Akirav, 2010; Akirav, 
2011; Trezza et al., 2012). Although the neurobiological mechanisms underlying 
cannabinoid manipulation of emotional and cognitive functions have not yet been 
completely elucidated, previous evidence demonstrates that the anxiolytic effects 
induced by pharmacological enhancement of endocannabinoid tone strongly depend on 
the emotional state at the time of testing (Patel and Hillard, 2006)and that these effects 
are modulated by the level of emotional reactivity induced by high or low aversive 
experimental conditions (Haller et al., 2009). To further shed light on the role of 
environmental aversiveness in cannabinoid modulation of emotionality and cognitive 
performance, we investigated whether exogenous manipulation of the endocannabinoid 
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system inﬂuences rat behavior in the Spatial Open Field task in experimental conditions 
characterized by either a HA or LA state. Our ﬁndings clearly show that the effects of the 
endocannabinoid transport inhibitor AM404 on cognitive responses in the Spatial Open 
Field test strongly depend on the level of emotionality at the time of testing. Indeed, 
AM404 administration impaired the rat capability to discriminate between a familiar and 
a new object only in rats exposed to the HA condition. Several studies have shown that 
CB1 receptor agonists produce anxiolytic- (Patel and Hillard, 2006; Scherma et al., 2008) 
or anxiogenic-like (Viveros et al., 2005; Patel and Hillard, 2006) effects, depending on the 
dose tested. Conversely, indirect cannabinoid agonists, that increase ongoing 
Endocannabinoid signaling by interfering with their deactivation, induce anxiolytic-like 
effects without anxiogenic responses also when administered at high doses. For instance, 
the FAAH inhibitor URB597 produces anxiolytic-like effects in the elevated zero-maze and 
in the ultrasonic vocalization test in rats (Kathuria et al., 2003). In accordance with these 
ﬁndings, FAAH knockout mice exhibit an anxiolytic-like phenotype in the elevated plus-
maze and in the light-dark box tests (Naidu et al., 2007; Moreira et al., 2008, 2009). 
Anxiolytic-like effects can also be induced by the inhibition of the endocannabinoid 
transport operated by endocannabinoid uptake inhibitors like AM404 (Beltramo et al., 
1997; Beltramo and Piomelli, 2000). Thus, it has been demonstrated that the systemic 
administration of AM404 produces anxiolytic-like effects in three rat models of anxiety: 
elevated plus maze, defensive withdrawal, and separation-induced ultrasonic vocalization 
tests, and these effects are blocked by the administration of the CB antagonist 
rimonabant (Bortolato et al., 2006; Patel and Hillard, 2006). Nevertheless, it should be 
noted that in an another study Moreira and co-workers (Moreira et al., 2007) found that 
co-administration of anandamide and AM404 in the rat periaqueductal gray (a brain 
structure related to aversive response) elicited anxiolytic-like responses in the elevated 
plus maze test, whereas AM404 alone did not. In the present study, we found that 
administration of AM404 did not inﬂuence the emotional parameters taken onto 
consideration in the Spatial Open Field test, like the time spent in the central part of the 
arena during the ﬁrst session of the task. However, it is important to note that, while 
AM404 administration did not inﬂuence the investigation of the objects through session 
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2–6 in a context characterized by a low-level of emotional activation, rats treated with the 
lower dose of AM404 and exposed to a stressful environment spent less time 
investigating objects, whereas the higher doses re-established the investigation activity at 
similar level of the vehicle-treated rats. The inhibition or the maintenance of the 
investigative behavior can be related to an anxiogenic or an anxiolytic phenotype, 
respectively (Crawley, 1985). It is possible to speculate that this biphasic effect may 
depend on a differential regulation activity on both GABAergic and gutamatergic neurons 
mediated by different doses of the Endocannabinoid transport inhibitor (Foldy et al., 
2007; Hashimotodani et al., 2007).  
Regarding the cognitive performance, here we show for the ﬁrst time that a 
pharmacologically-induced enhancement of endocannabinoid tone differentially 
modulates memory recognition in rats depending on different emotional states and 
different nature of the considered cognitive parameters (e.g., either spatial or novel 
object discrimination). Concerning the object displacement, although the results did not 
reach any statistical signiﬁcance it could be important to note that the treatment effect 
proﬁle resemble a trend of a typical U-shaped dose response curve, in accordance with 
other results showing a similar dose-dependent biphasic response induced by 
cannabinoids, particularly by anandamide (Sulcova et al., 1998) and by the psychoactive 
constituent of Cannabis sativa preparation Δ9-tetrahydrocannabinol (Onaivi et al., 1990; 
Valjent et al., 2001). Concerning the object substitution, the lower doses of AM404 
disrupted the ability to recognize a novel object in a stressful condition (HA) but not in a 
low arousal context (LA). It is well-established that the capability to recognize a new 
setting of the environment is important for species survival, but also that the impact of 
the object novelty ismore salient than a spatial rearrangement with the same objects 
(Mumby et al., 2002). However, the capability to discriminate a novel object in the arena 
can be lost under particular circumstances such as in a more stressful context, after 
repeated exposure to an aversive environment and experimental manipulation of the 
endocannabinoid tone as in the present study (Save et al., 1992;Mumby et al., 2002; 
Hebda-Bauer et al., 2010). These data conﬁrm previous ﬁndings showing similar effects in 
humans and laboratory animals where acute or chronic exposure to the psychoactive 
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constituent of cannabis, Δ9-tetrahydrocannabinol, induces impairment in cognitive 
function (Egerton et al., 2006; Ranganathan and D’Souza, 2006; Solowij and Battisti, 2008; 
Campolongo et al., 2009c, 2011; D’Souza et al., 2009; Sofuoglu et al., 2010). In rodents, 
cannabinoid direct agonists induce impairment in several cognitive performances such as 
spatial learning, working memory, and attentional processes (Presburger and Robinson, 
1999;Hampson and Deadwyler, 2000; Verrico et al., 2004; Robinson et al., 2007; Boucher 
et al., 2009, 2011). It is possible to speculate that these effects derive from cannabinoid-
mediated disruption of cortical and hippocampal activity, crucially involved in encoding of 
the stimulus and making cognitive associations (Robbe et al., 2006; Deadwyler et al., 
2007; Robbe and Buzsaki, 2009). The present results conﬁrm the hypothesis that 
cannabinoid drugs, depending on the dose tested and the emotional state of the subject, 
could induce different effects on short-term memory parameters. The dissimilar effects 
induced by exposure to a different emotional state could depend on the activation of the 
hypothalamic-pituitary-adrenal (HPA) axis triggered by a HA context and to the 
subsequent release of stress hormones, such as glucocorticoids. It is well known that this 
axis plays a crucial role in the stress response and that these hormones differentially 
modulate cognitive functions (Roozendaal and McGaugh, 1997; Mizoguchi et al., 2004; 
Atsak et al., 2011). In particular, de Quervain and co-workers (2009) reported that 
elevated glucocorticoid levels, elicited by aversive contexts, impair memory retrieval, and 
working memory.Moreover, further studies, conducted by our group, shed light on the 
crucial role of endocannabinoid signaling in the basolateral complex of the amygdala in 
modulating consolidation of aversive memory by an interaction with the glucocorticoid 
system (Campolongo et al., 2009a,b; Hill et al., 2010; Atsak et al., 2011).  
Taken together, the present ﬁndings support the hypothesis of a fundamental role of the 
environment in inﬂuencing both the behavioral and cognitive outcomes in the Spatial 
Open Field task. Most importantly, it emerges that drugs that enhance endocannabinoid 
signaling by interfering with endocannabinoid deactivation induce different effects on 
short-term memory performance depending on the level of emotional arousal induced by 
different environmental settings. 
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Abstract 
Signaling at NMDA receptors (NMDARs) is known to be important for memory 
reconsolidation, but while most studies show that NMDAR antagonists prevent memory 
restabilization and produce amnesia, others have shown that GluN2B-selective NMDAR 
antagonists prevent memory destabilization, protecting the memory. These apparently 
paradoxical, conflicting data provide an opportunity to define more precisely the 
requirement for different NMDAR subtypes in the mechanisms underlying memory 
reconsolidation and to further understand the contribution of glutamatergic signaling to 
this process. Here, using rats with fully consolidated pavlovian auditory fear memories, 
we demonstrate a double dissociation in the requirement for GluN2B-containing and 
GluN2A-containing NMDARs within the basolateral amygdala in the memory 
destabilization and restabilization processes, respectively. We further show a double 
dissociation in the mechanisms underlying memory retrieval and memory destabilization, 
since AMPAR antagonism prevented memory retrieval while still allowing the 
destabilization process to occur. These data demonstrate that glutamatergic signaling 
mechanisms within the basolateral amygdala differentially and dissociably mediate the 
retrieval, destabilization, and restabilization of previously consolidated fear memories. 
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Introduction 
Memory reconsolidation is the process by which previously consolidated memories 
become destabilized at retrieval and require restabilization to persist in the brain (Lewis, 
1979; Nader, 2003). The neurochemical basis of reconsolidation has been intensively 
studied, particularly the requirement for signaling at the NMDA subtype of glutamate 
receptor (NMDAR). However, although NMDAR-mediated signaling is required for the 
reconsolidation (restabilization) of conditioned stimulus (CS)–drug (Sadler et al., 2007; 
Brown et al., 2008; Itzhak, 2008; Milton et al., 2008; Milton et al., 2012), CS–spatial 
(Przybyslawski and Sara, 1997), and CS–fear (Pedreira et al., 2002; Lee et al., 2006) 
memories, antagonism at the GluN2B subtype of NMDAR has been shown to prevent the 
destabilization of CS–fear memories, thereby protecting them from the effects of 
amnestic agents (Ben Mamou et al., 2006). These paradoxical, apparently conflicting data 
provide the opportunity to better understand the contribution of signaling at 
glutamatergic receptors to the reconsolidation process.  
NMDARs exist as tetramers, typically composed of two GluN1 and two GluN2 subunits 
(Dingledine et al., 1999). The GluN2 subunits consist of four different types (GluN2A–D), 
of which GluN2A and GluN2B have been the most studied. In addition to differences 
between GluN2A-containing (GluN2A-NMDARs) and GluN2B-containing NMDARs 
(GluN2B-NMDARs) in their sensitivity to glutamate and their activation kinetics, these 
subtypes of receptor also couple to different proteins within the postsynaptic density, 
activating divergent intracellular signaling pathways (Kim et al., 2005; Ivanov et al., 2006; 
Zhang et al., 2008). For example, the C-terminal domain of GluN2B-NMDARs suppresses 
CREB and activates the ubiquitin–proteasome system (UPS), while GluN2A-NMDAR 
activation promotes CREB phosphorylation and is neuroprotective (Hardingham et al., 
2002; Martel et al., 2012). These differences at the molecular level may have important 
functional implications; activation of GluN2B-NMDARs promotes long-term depression 
(LTD), while activation of GluN2A-NMDARs promotes long-term potentiation (LTP) in the 
hippocampus (Liu et al., 2004).  
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The basolateral amygdala (BLA) is required for both CS–fear memory consolidation 
(Campeau and Davis, 1995; Killcross et al., 1997; Koo et al., 2004) and reconsolidation 
(Nader et al., 2000). Furthermore, NMDARs within the BLA have been implicated in both 
memory destabilization (Ben Mamou et al., 2006) and restabilization (Milton et al., 2008) 
processes. Thus, we hypothesized that memory destabilization and restabilization may be 
mediated through the different subtypes of NMDAR within the BLA, GluN2B-NMDARs 
being required for destabilization and GluN2A-NMDARs being required for restabilization. 
Furthermore, since AMPARs are required for memory retrieval (Day et al., 2003; Bast et 
al., 2005; Winters and Bussey, 2005) and because memory reconsolidation can only occur 
when a memory is retrieved (Lewis, 1979; Nader, 2003), we further hypothesized that 
AMPARs would be necessary for the destabilization process. Finally, we investigated the 
effects of reducing presynaptic glutamate release by treatment with an agonist at 
metabotropic 2/3 glutamate receptors (mGlu2/3Rs) on the balance of these mnemonic 
processes. We hypothesized that the memory should neither be retrieved nor 
destabilized, and therefore restabilization of the memory would not be required for it to 
persist.  
Materials and Methods 
Subjects. 
Subjects were 93 male Lister–Hooded rats (Charles River Laboratories) housed in pairs in a 
vivarium on a reversed light-dark cycle (lights on at 1900 h). Subjects were food restricted, 
although not deprived, being fed 25 g per rat of lab chow after training or testing each 
day. Access to water was ad libitum except for when inside the conditioning chambers. All 
procedures were conducted in accordance with the UK Animals (Scientific Procedures) Act 
1986.  
Surgery. 
Rats were implanted with bilateral guide cannulae (16 mm, 24 gauge; Coopers Needle 
Works) located just dorsal to the basolateral amygdala (Fig. 1) as described previously 
(Milton et al., 2008). The coordinates for cannula implantation were anteroposterior − 2.6 
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mm and mediolateral ± 4.5 mm (relative to bregma) and dorsoventral − 5.6 mm (relaƟve 
to dura). A recovery period of 7 days was given before behavioral training and testing 
began.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cannulae placements. All cannulae placements were within the BLA. The placements for 
individual experiments are shown separately. For each placement the white circles represent the 
vehicle/vehicle group, the white squares the vehicle/anisomycin group, the gray circles the 
drug/vehicle group, and the gray squares the drug/anisomycin group where the drugs were IFEN 
(a), NVP-AAM077 (b), LY293558 (c), and LY317206 (d). Coordinates are given from bregma. This 
figure was modified, with permission, from Paxinos and Watson (2004).  
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Intracerebral drug administration. 
Infusions were carried out using a syringe pump (Harvard Apparatus) and 5 µl Hamilton 
syringes connected to injectors (28 gauge, projecting 2 mm beyond the guide cannulae; 
Plastics One) by polyethylene tubing. The rats received two infusions: one immediately 
before the memory reactivation session, and one immediately afterward. All infusions 
were begun 30 s after the insertion of the injectors and performed over 2 min at a rate of 
0.25 µl min−1 (total volume of 0.5 µl side−1). One minute of waiting time was imposed from 
the end of the infusion to the removal of the injectors to allow diffusion of the solution 
away from the infusion site.  
Drugs. 
Rats received either the protein synthesis inhibitor anisomycin or its vehicle as their 
second (post-reactivation) infusion. Anisomycin (125 µg µl−1; Sigma-Aldrich) was dissolved 
in equimolar HCl and then pH balanced to pH 7.4 with NaOH. This dose of anisomycin has 
previously been shown to disrupt memory reconsolidation (Ben Mamou et al., 2006).  
Prior to memory reactivation, rats received infusions of drugs targeting the glutamatergic 
signaling system or the appropriate vehicle. The GluN2B diheteromeric receptor-selective 
(Williams, 1993) NMDAR antagonist ifenprodil (Ascent Scientific) was dissolved in PBS at a 
concentration of 2 µg µl−1; this dose has previously been shown to disrupt memory 
destabilization (Ben Mamou et al., 2006). The GluN2A-preferring (Auberson et al., 2002) 
NMDAR antagonist NVP-AAM077 (Sigma-Aldrich) was dissolved in PBS at a concentration 
of 5 µg µl−1; this dose has been shown to reduce the expression of fear-potentiated startle 
(Walker and Davis, 2008). The mGlu2/3R agonist LY317206 (Doherty et al., 1999) and the 
AMPAR antagonist LY293558 (Ornstein et al., 1993) were both generous gifts from Eli Lilly. 
LY317206 was dissolved in PBS at a concentration of 2 µg µl−1, and LY293558 in ddH2O at a 
concentration of 1.33 µg µl−1. This dose of LY317206 has been shown to reduce fear-
potentiated startle (Walker et al., 2002), and the dose of LY293558 is higher than the 
ineffective doses used previously in the amygdala (Di Ciano and Everitt, 2004).  
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Behavioral procedures 
Testing took place in four conditioning chambers (Med Associates) with the assignment of 
individual conditioning chambers counterbalanced across experimental groups within 
each experiment. Rats were first habituated to the context in a 2 h session in which 
neither the clicker CS nor the shock unconditioned stimulus (US) were presented. 
Following the end of this habituation session, they were returned to the home cage. 
Twenty-four hours later, they were placed back into the same experimental chamber for 
the fear conditioning session; during this time, they were first exposed to the context 
(with no CS or US) for 35 ± 1 min, then exposed to a single CS–US pairing of a clicker (10 
Hz, 80 dB, 60 s) CS and a 0.5 mA, 1 s scrambled footshock US. For the experiment 
investigating the requirement of AMPARs in memory reconsolidation, a different brand of 
experimental chamber (Paul Fray Limited) was used, but it was set up in the same 
configuration as the Med Associates chambers, other than the shock duration (0.5 s). To 
ensure comparability in the strength of learning, five CS-shock pairings were used in this 
experiment. All other aspects of the behavioral procedures remained the same.  
Twenty-four hours following the end of training, the rats were returned to the same 
conditioning chambers for a memory reactivation session. After 1 min of context 
exposure, the clicker CS was presented for 60 s. The session was recorded through a CCTV 
system onto a DVD to allow for offline manual scoring of behavior. Two CS–fear memory 
tests were conducted following the memory reactivation session; these test sessions, 
conducted 24 h and 8 d following reactivation, had the same format as the memory 
reactivation session, except that no drug infusions were given.  
Briefly, and as before (Ben Mamou et al., 2006), if memory destabilization was prevented 
by the pre-reactivation infusion, then anisomycin would not have an amnestic effect 
when it was subsequently infused, since the memory would not be in a destabilized and 
labile state when anisomycin was applied. If memory restabilization was prevented by the 
pre-reactivation infusion, then all experimental groups treated with the drug would be 
predicted to show amnesia at subsequent test, as would a group that had received an 
infusion of vehicle followed by anisomycin. If neither destabilization nor restabilization 
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were prevented by the pre-reactivation infusion, then only the two groups that had 
received post-reactivation anisomycin would be predicted to show amnesia.  
Histology 
At the end of the experiments, the rats were killed with an overdose of anesthetic 
(Dolethal, Vétoquinol) and transcardially perfused through the ascending aorta with 0.01 
m PBS, followed by 4% paraformaldehyde (PFA). The brains were removed and stored in 
4% PFA for at least 24 h before being transferred to a 20% sucrose solution for 
cryoprotection before sectioning. The brains were sectioned at 60 µm and stained with 
cresyl violet. Cannulae placements (Fig. 1) were verified using light microscopy (Leica).  
Data collection and statistical analysis 
Data for the reactivation and test sessions were scored offline and blind to treatment by 
A.L.M. Data from the conditioning session were not recorded because there is no measure 
of conditioned freezing when animals receive only one pairing of the CS with shock. 
However, shock delivery was recorded by the experimenter observing the unconditioned 
response in the conditioning session. Freezing was defined as a cessation of movement 
apart from respiration and was measured instantaneously at 5 s intervals. Freezing during 
the first minute of the session was assessed to provide a measure of fear to the context, 
and the second as a measure of fear to the CS. All data were converted to percentages 
before analysis. Data were analyzed by repeated-measures ANOVA with CS (context vs 
cue) and Session (reactivation vs 24 h test vs 8 d test) as within-subject factors, and Drug 1 
[vehicle (VEH) vs drug] and Drug 2 [VEH vs anisomycin (ANI)] as between-subjects factors. 
For clarity, these are reported in the text using the name of the drug used in the 
experimental group (e.g., Drug 2 is shown as ANI). Where the data violated the 
assumption of sphericity as assessed using Mauchly's test, a correction was applied; the 
Greenhouse–Geisser correction if ε < 0.75, and the Huynh–Feldt correction if ε > 0.75, as 
recommended by Cardinal and Aitken (2006). Where appropriate, further ANOVAs or 
pairwise comparisons were conducted; all pairwise comparisons were adjusted using the 
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Šidák correction, which is a mathematically accurate form of the Bonferroni estimation 
(Cardinal and Aitken, 2006).  
Results 
GluN2B-NMDARs are required for memory destabilization, not restabilization 
Administration of the GluN2B-selective NMDAR antagonist ifenprodil (IFEN) directly into 
the BLA before memory reactivation prevented the destabilization of the CS–fear 
memory. This was shown by the prevention of anisomycin-induced amnesia when IFEN 
was given before reactivation, but not when the vehicle was given before reactivation 
(Fig. 2b). All groups had previously conditioned to the CS, as all rats showed greater 
freezing to the CS than the context in the reactivation and the test sessions [F1, 25 = 33.0, p 
< 0.001, η2 = 0.57]. While the VEH/ANI group showed less freezing than the VEH/VEH 
group at the 24 h test [F(1, 14) = 5.8, p = 0.031, η2 = 0.29], the IFEN/ANI group froze 
comparably to the IFEN/VEH group [F < 1, p = 0.66]. Analysis of the 8 d test was 
complicated by an overall reduction in conditioned freezing [CS × session: F1, 25 = 4.7, p = 
0.04, η2 = 0.16] most likely attributable to the gradual extinction that occurred after the 
last nonreinforced retrieval test. However, while the VEH/VEH and VEH/ANI groups 
showed equivalent conditioned freezing at the 8 d test [F1, 14 = 2.2, p = 0.16], so did the 
IFEN/VEH and IFEN/ANI groups [F1, 11 = 3.4, p = 0.09], consistent with the prevention of 
destabilization of the CS–fear memory by IFEN.  
IFEN did not acutely affect the retrieval of the conditioned fear memory (Fig. 2a); 
collapsing across groups for the first infusion (VEH, n = 16; IFEN, n = 13) there was no 
difference in the level of conditioned freezing shown during the memory reactivation 
session [F < 1, p = 0.95]. These findings confirm the previous report (Ben Mamou et al., 
2006) that GluN2B-NMDARs are required for memory destabilization. 
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Figure 2. Effects of the GluN2B-selective NMDAR antagonist on CS–fear memory reconsolidation. 
Administration of the GluN2B-selective NMDAR antagonist had no effect on the retrieval of the CS–
fear memory at reactivation (a), but it did prevent the destabilization of the CS–fear memory (b). 
Data are presented as means ± SEM. Group sizes (and colors in b) were VEH/VEH, n = 8 (white); 
IFEN/VEH, n = 8 (mid-gray); VEH/ANI, n = 8 (pale gray); and IFEN/ANI, n = 5 (dark gray). In a the 
groups are collapsed with the white bar representing the average of the VEH/VEH and VEH/ANI 
groups, and the gray bar the IFEN/VEH and IFEN/ANI groups. Asterisk (*) denotes p < 0.05.  
GluN2A-NMDARs are required for memory restabilization, not destabilization 
Administration of the GluN2A-preferring NMDAR antagonist NVP-AAM077 (NVP) before 
the memory reactivation session reduced conditioned freezing at subsequent tests 
conducted 24 h and 8 d later (Fig. 3b). All rats had conditioned to the CS, as all groups 
showed greater freezing to the CS than the context in the reactivation and the test 
sessions [F1, 15 = 12, p = 0.003, η2 = 0.45]. Administration of NVP reduced conditioned 
freezing in the subsequent test sessions [CS × Session × NVP: F2, 30 = 4.8, p = 0.016, η2 = 
0.24], but not during the reactivation session. Analyses of individual sessions showed that 
there were no differences between experimental groups during reactivation [CS × NVP: F1, 
15 = 2.3, p = 0.15; CS × ANI: F < 1, p = 0.52; CS × NVP × ANI: F < 1, p = 0.87], but NVP-
treated animals froze less than VEH-treated rats during the test at 24 h [CS × NVP: F1, 15 = 
8.5, p = 0.011, η2 = 0.36]. The effect of NVP was persistent in that there was no overall 
reduction in freezing between the 24 h and the 8 d test [F< 1], although there was a 
reduction in the VEH-treated groups [CS × Session × NVP: F1, 15 = 9.75, p = 0.007, η2 = 0.39; 
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pairwise comparisons showed a reduction in conditioned freezing between the 24 h and 8 
d test in the VEH-treated groups, p = 0.024, but not in the NVP-treated groups, p = 0.22]. 
This is consistent with extinction of the CS–US association in the VEH/VEH group, but not 
in the other experimental groups, which could not reduce freezing any further. Pairwise 
comparisons also revealed that the NVP-treated groups did not differ from the VEH/ANI 
group [all p values > 0.41]. Thus, administration of NVP produced amnesia regardless of 
whether anisomycin was also administered. Furthermore, the amnesia shown by the 
NVP/ANI group supports the view that NVP did not block destabilization, because if it had 
then this group would have shown intact memory.  
NVP did not acutely affect the retrieval of the conditioned fear memory during the 
reactivation session (Fig. 3a); collapsing across groups for the first infusion (VEH, n = 9; 
NVP, n = 10), despite the apparent numerical reduction in freezing in the NVP-treated 
group, there was no statistical difference between freezing levels in the two experimental 
groups [F1, 17 = 2.4, p = 0.14]. However, the NVP-treated group showed levels of freezing 
that did not significantly differ from zero [p = 0.34] consistent with the previous 
observation that this dose of NVP reduces the expression of fear-potentiated startle 
(Walker and Davis, 2008). This result supports our hypothesis that GluN2A-NMDARs are 
required for memory restabilization while not being required for memory destabilization. 
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Figure 3. Effects of the GluN2A-preferring NMDAR antagonist on CS–fear memory reconsolidation. 
Administration of the GluN2A-preferring NMDAR antagonist had no effect on the retrieval of the 
CS–fear memory at reactivation (a), but it prevented the restabilization of the CS–fear memory (b). 
Data are presented as means ± SEM. Group sizes (and colors in b) were: VEH/VEH, n = 4 (white); 
NVP/VEH, n = 5 (mid gray); VEH/ANI, n = 5 (pale gray); and NVP/ANI, n = 5 (dark gray). In a the 
groups are collapsed, with the white bar representing the average of the VEH/VEH and VEH/ANI 
groups, and the gray bar the NVP/VEH and NVP/ANI groups. Asterisk (*) denotes p < 0.05; ns 
denotes nonsignificant differences 
AMPARs are not required for destabilization or restabilization 
Administration of the AMPAR antagonist LY293558 before memory reactivation did not 
reduce conditioned freezing during the test sessions and did not prevent the post-
reactivation anisomycin infusion from inducing amnesia (Fig. 4b). All rats had conditioned 
to the CS, as they showed greater freezing to the CS than the context following training 
[F1, 21 = 37.7, p < 0.001, η2 = 0.64]. LY293558 did not affect freezing in the 24 h test session 
[CS × LY293558: F < 1, p = 0.45], but anisomycin infusion resulted in amnesia [CS × ANI: F1, 
21 = 16, p = 0.001, η2 = 0.44]. Indeed, the group that received anisomycin following 
LY293558 froze less than the group that received vehicle before reactivation [CS × ANI: F1, 
9 = 6.0, p = 0.037, η2 = 0.40], demonstrating that LY293558 did not prevent the 
destabilization of the memory. This anisomycin-induced amnesia was also observed at the 
8 d test [F1, 21 = 7.82, p = 0.011, η2 = 0.27], even though there was extinction of 
conditioned freezing at the 8 d test compared to the 24 h test [F1, 21 = 10.1, p = 0.005, η2 = 
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0.32]. This is consistent with a previous report in which the AMPA/kainate receptor 
antagonist CNQX was shown to leave memory destabilization and restabilization intact 
when given before memory reactivation (Ben Mamou et al., 2006).  
LY293558 acutely reduced conditioned freezing during the memory-reactivation session 
(Fig. 4a); collapsing across groups for the first infusion (VEH, n = 14; LY293558, n = 11), the 
groups given LY293558 before the memory reactivation froze to the CS less than groups 
that had received the infusion of vehicle [CS × LY293558: F1, 23 = 6.8, p = 0.016, η2 = 0.23]. 
Thus, AMPARs are required for memory retrieval but not memory destabilization. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effects of the AMPAR antagonist on CS–fear memory reconsolidation. The AMPAR 
antagonist LY293558 acutely impaired the retrieval of the CS–fear memory at reactivation (a), but 
it affected neither the destabilization nor the restabilization of the CS–fear memory (b). Group 
sizes (and colors in b) were VEH/VEH, n = 8 (white); LY293558/VEH, n = 6 (mid gray); VEH/ANI, n = 6 
(pale gray); and LY293558/ANI, n = 5 (dark gray). In a the groups are collapsed, with the white bar 
representing the average of the VEH/VEH and VEH/ANI groups and the gray bar the LY293558/VEH 
and LY293558/ANI groups. Asterisks (*) denote p < 0.05.  
Blockade of Glu release left destabilization and restabilization intact 
LY317206, an agonist at presynaptic class II/III metabotropic glutamate receptors 
(mGlu2/3Rs), affected neither the destabilization nor the restabilization of the CS–fear 
memory (Fig. 5b). All groups had conditioned to the CS during training, as shown by 
increased freezing during the CS compared to the context [F1, 16 = 29, p < 0.001, η2 = 0.64]. 
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However, although anisomycin produced amnesia as assessed at the 24 h test [CS × ANI: 
F1, 16 = 7.2, p = 0.016, η2 = 0.31], there was no effect of LY317206 on conditioned freezing 
[CS × LY317206: F < 1, p = 0.74], indicating that it did not prevent the restabilization of the 
CS–fear memory. Furthermore, as the LY317206/ANI group showed less freezing to the CS 
than the LY317206/VEH group at the 24 h test [CS × ANI: F1, 10 = 11, p = 0.008, η2 = 0.52], 
the memory destabilized during the reactivation session, and this process was not 
prevented by agonism at mGlu2/3Rs. The anisomycin-induced amnesia observed at 24 h 
persisted at the trend level in the 8 d test [F1, 16 = 4.14, p = 0.059, η2 = 0.21], although the 
data from the 8 d test were compromised by the extinction of conditioned freezing in the 
VEH/VEH group [pairwise comparisons revealed reduced conditioned freezing at the 8d 
test in this group, p = 0.035, but no differences in the other groups, all p values > 0.49]. 
LY317206 did not acutely affect the retrieval of the conditioned fear memory during the 
reactivation session (Fig. 5a); collapsing across groups for the first infusion (VEH, n = 8; 
LY317206, n = 12), there was no statistically significant difference between freezing levels 
in the two groups [F1, 18 = 2.4, p = 0.14] despite the numerical reduction in conditioned 
freezing. Thus, agonism at presynaptic mGlu2/3Rs did not affect the destabilization or 
restabilization and did not produce a statistically significant reduction in the retrieval of 
the CS–fear memory. 
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Figure 5. Effects of the mGlu2/3R agonist on CS–fear memory reconsolidation. The mGlu2/3R 
agonist LY317206 did not prevent retrieval of the CS–fear memory at reactivation (a), and it 
prevented neither destabilization nor restabilization of the CS–fear memory (b). Group sizes (and 
colors in b) were VEH/VEH, n = 4 (white); LY317206/VEH, n = 6 (mid gray); VEH/ANI, n = 4 (pale 
gray); and LY317206/ANI, n = 6 (dark gray). In a the groups are collapsed, with the white bar 
representing the average of the VEH/VEH and VEH/ANI groups and the gray bar the LY317206/VEH 
and LY317206/ANI groups. Asterisk (*) denotes p < 0.05; ns denotes nonsignificant differences.  
Discussion 
The present data support the view that GluN2B-NMDARs and GluN2A-NMDARs within the 
BLA are required for memory destabilization and restabilization, respectively. This is the 
first demonstration of a double dissociation in the function of these two subtypes of 
NMDAR in memory reconsolidation. Furthermore, we also demonstrate a double 
dissociation between memory retrieval (dependent upon AMPARs) and the induction of 
memory lability (dependent upon GluN2B-NMDARs).  
The doubly dissociable involvement of different NMDAR subtypes in destabilization and 
restabilization enables resolution of the apparent discrepant findings in the literature that 
antagonism at GluN2B-NMDARs prevents memory destabilization (Ben Mamou et al., 
2006), but that nonselective NMDAR antagonism with d-APV (Milton et al., 2008) or MK-
801 (Przybyslawski and Sara, 1997; Pedreira et al., 2002; Sadler et al., 2007; Brown et al., 
2008; Itzhak, 2008; Lee and Everitt, 2008; von der Goltz et al., 2009) prevents the 
restabilization of memories. We hypothesize (Fig. 6) that the differential effects of 
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nonsubtype-selective NMDAR antagonists on these mnemonic processes depend upon 
the balance between signaling at GluN2B-NMDARs and GluN2A-NMDARs, since only after 
the brief destabilization process is there a requirement for the longer-lasting 
restabilization process to be engaged. The differences in duration of the two processes, 
subserved by different subpopulations of NMDAR expressed within BLA neurons (Müller 
et al., 2009), would suggest that the nonsubtype-selective NMDAR antagonists tested in 
previous studies appear to be sufficient to prevent GluN2A-dependent signaling, but fail 
significantly to affect GluN2B-dependent signaling.  
Thus, we hypothesize that nonselective NMDAR antagonists exert their amnestic effects 
primarily through GluN2A-containing NMDARs. Consistent with this view are the findings 
that GluN2A-preferring NMDAR antagonists prevent the acquisition of spatial memory (Hu 
et al., 2009) and conditioned fear (Dalton et al., 2012), as do nonsubtype-selective 
NMDAR antagonists (Morris et al., 1986; Davis et al., 1992; Fanselow and Kim, 1994). 
Furthermore, the effects of nonselective NMDAR antagonists on other processes, such as 
cortical oscillations, are more similar to the effects of GluN2A-preferring NMDAR 
antagonists than GluN2B-selective NMDAR antagonists (Kocsis, 2012). Thus, the 
glutamate transmission-dependent destabilization and restabilization processes would be 
predicted to engage parallel, independent molecular mechanisms mediated by the two 
subtypes of NMDAR. This perspective can be integrated with already known mechanisms 
underlying memory destabilization; for example, GluN2B-containing NMDARs recruit the 
ubiquitin-proteasome system via CaMKII (Bingol et al., 2010), thus allowing the protein 
degradation that is required for the induction of memory lability (Lee et al., 2008) 
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Figure 6. Hypothesized glutamatergic mechanisms underlying memory stability. GluN2B-containing 
NMDARs are required for memory destabilization, and IFEN prevents this process. GluN2A-
containing NMDARs are required for memory restabilization, which is prevented by NVP-AAM077. 
The AMPAR antagonist LY293558 reduces memory retrieval but has no effect on destabilization or 
restabilization. The presynaptic mGlu2/3R agonist LY317206 reduces glutamate release, reducing 
memory retrieval via AMPARs but leaving the balance of GluN2A and GluN2B activity intact (thus 
having no effect on destabilization or restabilization).  
Surprisingly, we found a further dissociation in the mechanisms underlying memory 
retrieval (dependent upon AMPARs) and destabilization (dependent upon GluN2B-
NMDARs). These data refute our original hypothesis concerning AMPARs, although they 
are consistent with previous findings that signaling via AMPARs is necessary for memory 
expression and retrieval (Day et al., 2003; Bast et al., 2005; Winters and Bussey, 2005). It 
is perhaps surprising, from a theoretical perspective, that memory retrieval and 
destabilization might be disrupted independently, since reconsolidation theories maintain 
that memories must be retrieved to become once again susceptible to disruption with 
amnestic agents (Lewis, 1979; Nader, 2003). We therefore propose that the processes of 
memory retrieval and memory destabilization are doubly dissociable, but that behavioral 
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procedures used to induce memory destabilization often induce memory retrieval as well. 
This hypothesis clearly warrants further investigation.  
As predicted, the LY317206-induced reduction in glutamate release (Doherty et al., 1999) 
resulted in decreased activity at AMPARs, GluN2B-NMDARs, and GluN2A-NMDARs and 
hence no observable effect on memory retrieval, destabilization, or restabilization. 
Although this is consistent with the mechanisms shown in Figure 6, these data also 
indicate that such drugs are unlikely to have utility in the treatment of maladaptive 
memories that characterize some neuropsychiatric disorders. There has been interest in 
indirectly modulating signaling at NMDARs by reducing glutamate release presynaptically 
since, as has been noted previously (Milton and Everitt, 2010), systemic NMDAR 
antagonists are unlikely to be used clinically because of their problematic 
psychotomimetic side effects. However, our data do support the view that selectively 
targeting GluN2A-NMDARs may provide a useful therapeutic strategy; the 
psychotomimetic effects of systemic NMDAR antagonism are likely mediated through 
GluN2B-NMDARs (De Vry and Jentzsch, 2003), and so it may be possible to develop 
GluN2A-NMDAR-selective therapies that are appropriate for clinical use.  
The results of these experiments reveal the complexity of the glutamatergic mechanisms 
underlying CS–fear memory reconsolidation within the BLA. In summary, GluN2A-
containing and GluN2B-containing NMDARs have dissociable roles in memory 
restabilization and destabilization, respectively. While AMPARs are required for memory 
retrieval, they do not appear necessary for memory destabilization, suggesting that these 
two processes are independently regulated. Furthermore, agonism at presynaptic 
mGlu2/3Rs has no overall effect on the strength of a CS–fear memory. In addition to 
further elucidating the glutamatergic mechanisms underlying the reconsolidation of fear 
memories, these data also further support the possible utility of modulating specific 
glutamate receptors in the clinical treatment of anxiety disorders to disrupt persistent 
maladaptive and intrusive memories.  
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Introduction 
Memory reconsolidation refers to a process through which a previously consolidated and 
recalled memory turns into a labile state and become susceptible to being manipulated. 
Thus, this instability could result in newly strengthened and/or integrated or disrupted 
memories. For example, pharmacological manipulation before or immediately after 
retrieval, could prevents (Debiec et al, 2002; Milton et al, 2013; Nader et al, 2000; 
Taubenfeld et al, 2009; Wang et al, 2009) or enhances the expression of conditioned fear 
response (Lee et al, 2006b). That is, manipulation of reconsolidation process could be 
used as a novel tool to disrupt maladaptive memories in neuropsychiatric disorders, such 
as post-traumatic stress disorder, in humans (Brunet et al, 2008; Debiec and LeDoux, 
2006; Oyarzun et al, 2012; Schiller et al, 2010).  
Growing evidence indicates a fundamental involvement of the endocannabinoid system in 
regulation of memory processing of emotionally salient events (Atsak et al, 2012; 
Campolongo et al, 2009b; Campolongo and Trezza, 2012b; Hauer et al, 2011). This is 
consistent with the localization of cannabinoid receptors (CB) throughout the cortico-
limbic system, in brain regions involved in regulation of learning and memory such as 
hippocampus, basolateral amygdala (BLA) and prefrontal cortex. Recently it has been 
shown that bilateral intra-BLA infusion of the direct cannabinoid receptor agonist 
WIN55,212-2 immediately after inhibitory avoidance training enhances memory 
consolidation in rats (Campolongo et al, 2009b). However, the use of drugs that directly 
bind and activate brain cannabinoid receptors may be limited by their abuse liability. 
Indirect cannabinoid agonists, that increase endocannabinoid signalling by interfering 
with endocannabinoid degradation/transport, are emerging as a new pharmacological 
tool. The enhancing effect on memory consolidation has been confirmed recently by the 
enhancement of memory consolidation, induced by potentiation of the endocannabinoid 
tone, through inhibition of the enzyme responsible of endogenous cannabinoid 
degradation Fatty Acid Amide Hydrolase (FAAH). The indirect cannabinoid agonist 
URB597, a FAAH-inhibitor agent, bilaterally infused in the BLA, enhanced consolidation for 
aversive memory and this effect is prevented by blocking CB1 receptors with infusion of 
the CB1 receptor antagonist AM251 (Ratano et al, 2011). 
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However, the role of endocannabinoid system in memory reconsolidation is still poorly 
understood. Indeed, evidence indicates that the activation or inactivation of 
endocannabinoid receptors bidirectionally modulate memory reconsolidation of aversive 
events (de Oliveira Alvares L. et al, 2008; Kobilo et al, 2007; Lin et al, 2006; Suzuki et al, 
2008). However, while the CB1 receptor agonist, WIN 55,212-2 was reported to impair 
reconsolidation of fear-potentiated startle after CS re-exposure (Lin et al, 2006), the CB1 
receptor antagonist rimonabant did not enhance memory or produce amnesia, suggesting 
that CB1 receptors are not required for memory reconsolidation (Suzuki et al, 2004). In a 
more recent study, Stern and co-workers demonstrate that the phytocannabinoid 
cannabidiol is able to disrupt contextual fear memories when systemically administered 
immediately after memory reactivation (Stern CA et al, 2012) suggesting that the effect 
induced by cannabidiol is possibly dependent on cannabinoid type-1 receptor-mediated 
signaling mechanisms. 
However these poor and contrasting findings do not help in clarifying how the 
endocannabinoid system is involved in reconsolidation process. In order to better 
understand how the endocannabinoid system influence memory reconsolidation, in the 
present study we aimed to evaluate the effects of the endocannabinoid system 
manipulation directly within the basolateral amygdala on reconsolidation of pavlovian 
fear memory in an auditory fear conditioned paradigm, as well as the mechanisms 
underlying memory processing after cue re-exposure during memory recall. Moreover, as 
it is known that CB1 receptors localize presynaptically in the BLA on a distinct 
subpopulation of GABAergic interneurons (Katona et al, 2001), interaction between 
endocannabinoid and GABAergic neurotransmission was evaluated in order to investigate 
the mechanisms underlying the effects on memory reconsolidation after pharmacological 
manipulation of CB1 receptors. 
Materials and Methods 
Subjects.  
112 Male Lister-Hooded rats (300-320 at the time of surgery, Charles River) were housed 
in pairs in a vivarium on a reversed light-dark cycle (lights on at 1900hrs). All subjects 
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were food restricted, but not deprived, being fed 25 g per rat of lab chow after training or 
testing each day starting from the day of surgery. Access to water was ad libitum except 
for when inside the conditioning chambers and during infusion procedure. All procedures 
were conducted in accordance with the UK Animals (Scientific Procedures) Act 1986 and 
the Directive 2010/63/EU of the European Parliament and of the Council of 22 September 
2010 on the protection of animals used for scientific purposes. 
Surgery.  
Rats were anesthetized with intramuscular injection of a mixture of ketamine (80mg/kg) 
and xylazine (10mg/kg) and implanted with bilateral guide cannulae (16mm, 24 gauge; 
Coopers Needle Works Ltd) located just dorsal to the basolateral amygdala as described 
previously (Milton et al, 2008a). The co-ordinates for cannula implantation were AP - 2.6 
mm and ML ± 4.5 mm (relative to bregma) and DV – 5.6 mm (relative to dura). Stainless 
steel obdurators were inserted into both cannulae to maintain patency. A recovery period 
of at least 7 days was given prior to behavioral testing.  
Drug infusion. 
Intra-BLA administration was carried out using a syringe pump (Harvard Apparatus) and 5 
µl Hamilton syringes, connected to injectors (28 gauge, projecting 2 mm beyond the guide 
cannulae; Plastics One Inc.) by polyethylene tubing. All infusions were begun 30 seconds 
after the insertion of the injectors and performed over 2 minutes at a rate of 0.25 µl min-1 
(total volume of 0.5 µl side-1). One minute of waiting time was imposed from the end of 
the infusion to the removal of the injectors to allow the drugs to diffuse from the injection 
site. The CB1 receptor agonist URB597 (Cyclohexylcarbamic acid 3´-carbamoyl-biphenyl-3-
yl ester , Sigma-Aldrich ,30 ng per 0.5 µL per side), the CB1 receptor antagonist AM251 (N-
(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3 
carboxamide, Tocris, 300 ng per 0.5 µL per side) and GABAA receptor antagonist 1(S),9(R)-
(−)-Bicuculline methiodide (bic, Sigma, 50 ng per 0.5 µL per side) were dissolved in a 
vehicle (veh) containing 5% polyethylene glycol, 5% Tween-80 and 90% saline. All doses 
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were chosen based on previous studies (Koya et al, 2009) and on data from pilot 
experiments.  
Histology 
After completion of behavioral testing, the rats were killed with a dose of anaesthetic and 
transcardially perfused with 0.01 M PBS, followed by 4% paraformaldehyde (PFA). Brains 
were collected and stored in 4% PFA for at least 24 hours, before being transferred to 20% 
sucrose solution for cryoprotection prior to sectioning. Subsequently, the brains were cut 
to produce 60 µm coronal sections, and stained with Cresyl Violet. The cannulae 
placement assessment was conducted under light microscopy (Leica), and subjects were 
only included in the statistical analysis if the injectors were located bilaterally within the 
BLA, and there was no bilateral damage to the amygdala or any other area of the brain. 
Behavioural procedures. 
Auditory Fear Conditioning was performed in four operant chambers (Med Associates 
Inc.). On day 1 (habituation session), the rats were habituated to the experimental 
chamber for 2 hours and allowed to freely explore the context. On day 2, for fear 
conditioning (conditioning session), the rats were placed in the same experimental 
context as in the habituation session, and exposed to two CS-US pairings. The CS was an 
auditory clicker (10 Hz, 80 dB, 60 s) and the US a mild electric footshock (0.5 mA, 1 s). The 
first CS-US pairing was presented after 35 ± 1 minute from the start of the session, 
followed by a 5± 1 minute interval when a second CS-US pairing was given. The 
conditioning session terminated 5 minutes after the last footshock delivery. On day 3, for 
memory reactivation (reactivation session), the rats were exposed during a brief 2 min 
session to a single presentation of the 60 s CS after 60 s of context exposure. All rats 
received an intra-BLA infusion of the drugs before or immediately after the memory 
reactivation session to evaluate the effect of the drugs on memory reconsolidation 
process. As control, an additional group of non-reactivated rats were habituated and 
conditioned following the same behavioral procedure except for receiving drug injections 
in the holding room on day 3 without being exposed to the reactivation session. The 
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conditioned freezing was tested during a single presentation of the 60 s CS after 60 s of 
context exposure (testing sessions). Testing took place 24 h [post-reactivation long-term 
memory (PR-LTM24h), day 4], and 8 days (PR-LTM8d, day 8) after memory reactivation to 
test long-term memory retention. Freezing behaviour was video-recorded, the 
behavioural outcome subsequently scored offline by an observer unaware of drug 
treatment, and analyzed for freezing. Freezing is defined as the lack of movement except 
for breathing at 5 s intervals to give the percentage time freezing during the CS. Freezing 
during the first minute of the testing session was assessed as measure of fear reaction to 
the experimental context, and during the second as measure of fear to the CS. 
Statistical Analysis 
Data were analyzed by repeated measures ANOVA, with CS (Context vs. Cue) and Session 
(Reactivation vs. PR-LTM24hvs. PR-LTM8d) as within-subject factors, and Treatment (VEH 
vs. URB597 vs. AM251) as between-subjects factors. Where the data violated the 
assumption of sphericity as assessed using Mauchly’s test, a correction was applied; the 
Greenhouse-Geisser correction if ε < 0.75, and the Huynh-Feldt correction if ε > 0.75, as 
recommended by Cardinal & Aitken (2006). Where appropriate, further ANOVAs or 
pairwise comparisons were conducted; all pairwise comparisons were adjusted using the 
Šidák correction, which is a mathematically accurate form of the Bonferroni estimation 
(Cardinal et al, 2006). 
Results 
Pre-reactivation infusion of URB597 and AM251 did not affect retrieval and 
reconsolidation of pavlovian fear memory. 
To evaluate the role of the endocannabinoid system in the BLA on the modulation of fear 
memory reconsolidation, the CB1 indirect agonist URB597 or the CB1 antagonist AM251 
was bilaterally infused into the BLA 30 min before the reactivation session. All 
experimental groups had previously conditioned to CS, as all rats showed a greater fear 
response to the CS than to the context during the reactivation session (F1,25=41.59; 
p<0.001). As shown in Fig. 1, there were no differences in conditioned freezing during the 
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test sessions between animals given URB, AM or vehicle (F2,25=0.98; p=0.39), and though 
conditioned freezing reduced across the test sessions (F2,50=5.83; p<0.005), it did so in a 
similar way across all experimental groups (F4,50=0.06; p=0.99). Pairwise comparisons 
revealed that there was a statistically significant difference in levels of freezing of all 
treated rats between the reactivation session and PR-LTM8d (reactivation vs PR-LTM8d, 
p=0.012) and between PR-LTM24h and PR-LTM8d (PR-LTM24h vs PR-LTM8dPR-LTM8d, 
p=0.02) sessions. This might indicates that repeated exposure without reinforcing could 
activate an extinction process inducing a reduction of the fear response. Moreover, 
ANOVA on the single reactivation session did not reveal a treatment effect on freezing 
levels (F2,25=0.41; p=0.67) showing that the pre-infused drugs did not acutely affect the 
expression of conditioned freezing. Therefore, neither URB597 nor AM251, at the doses 
used, affected retrieval or memory reconsolidation, as all groups showed the same level 
of freezing response over the reactivation and test sessions. 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Effects of the indirect CB1 agonist URB597 (30ng/0.5ul) and the CB1 antagonist AM251 
(300ng/0.5ul) on CS–fear memory reconsolidation. Administration of URB597 (30ng/0.5ul) or 
AM251 (300ng/0.5ul) before reactivation session had no effect on the retrieval of the CS–fear 
memory at reactivation and did not alter expression of freezing response 24h or 8d post-
reactivation. Data are presented as means ± SEM. Group sizes were veh, n = 9; URB597 
(30ng/0.5ul), n = 10; AM251 (300ng/0.5ul), n = 9  
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Immediately post-reactivation infusion of the CB1 antagonist AM251 disrupted 
reconsolidation of pavlovian fear memory 
The CB1 antagonist AM251 infused in BLA immediately post-reactivation session 
disrupted memory reconsolidation of pavlovian fear memory. All rats had previously 
conditioned to CS, as all groups showed a greater fear response to the CS than to the 
context during the reactivation session (F1,29=5.52; p<0.001). As shown in Fig. 2, there 
were differences in conditioned freezing during the test sessions between animals given 
URB597, AM251 or vehicle (F2,29=6.00; p=0.007) and across both test sessions (F2,29=4.78; 
p=0.012) and all experimental groups (F4,58=5.53; p=0.001) Pairwise comparisons revealed 
that rats infused with AM251 immediately after the reactivation session froze less when 
re-exposed to the context 24h later (PR-LTM24h vs reactivation p=0.011) and 8 days later 
(PR-LTM7d vs reactivation p=0.001) when compared with the same rats exposed to the CS 
prior to the treatment. Additionally, pairwise comparisons showed that rats administered 
with URB597 had higher levels of freezing when re-exposed to the CS 24h after memory 
reactivation (PR-LTM24h vs reactivation, p=0.041) when compared with the same group 
prior to the treatment. However this fear response was not a persistent effect over the 
time as when re-exposed to the CS 8 days post-reactivation URB597-treated rats showed 
the same freezing response as the same group prior to the infusion (PR-LTM8d vs 
reactivation, p=0.96). Moreover, analyses of single test sessions showed a significant main 
effect of treatment for both PR-LTM24h (F2,29=12.033, p<0.001) and PR-LTM8d 
(F2,29=6.819, p=0.004). Post hoc analysis showed that AM251-treated rats had freezing 
levels significantly lower when compared with vehicle and URB597-treated rats after both 
24h (p=0.005; p<0.001 respectively) and 8d (p=0.038; p=0.004, respectively) the 
reactivation session. Thus, intra-BLA infusion of the indirect CB1 agonist URB597 seems to 
potentially enhance memory reconsolidation while the antagonist AM251 had an 
opposite effect and persistently disrupted reconsolidation of pavlovian fear memory. 
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Fig. 2 Effects of the indirect CB1 agonist URB597 (30ng/0.5ul) and the CB1 antagonist AM251 
(300ng/0.5ul) on CS–fear memory reconsolidation. Administration of URB597 (30ng/0.5ul) 
immediately after the reactivation session had no effect on CS–fear memory reconsolidation both 
24h and 8d after reactivation. AM251 (300ng/0.5ul) persistently impaired memory reconsolidation 
when compared with vehicle and URB597 (30ng/0.5ul)-treated rats after both 24h and 8d after the 
reactivation session (**p<0.01 vs veh; $$$ p<0.001 vs URB597 (30ng/0.5ul)) (*p<0.05 vs veh; $$ 
p<0.01 vs URB597 (30ng/0.5ul)). Data are presented as means ± SEM. Group sizes were veh, n = 10; 
URB597 (30ng/0.5ul), n = 12; AM251 (300ng/0.5ul), n = 10 
Disruption of memory reconsolidation induced by intra-BLA AM251 administration was 
dependent on memory reactivation. 
To establish that the disruption of memory reconsolidation is dependent on the 
reactivation process, different groups of rats were infused with the same doses of URB597 
or AM251 or vehicle, but were not exposed to the memory reactivation session. All rats 
had previously conditioned to CS, as all groups froze more during the CS presentation 
than to the context during the reactivation session (F1,21=23.454; p<0.001). ANOVA did not 
reveal a significant main effect of treatment (F2,21=0.024; p=0.976) but showed a 
significant main effect of session (PR-LTM24h vs PR-LTM8d, F1,21=5.931; p=0.024) and a 
significant interaction session x treatment effect (F2,21=4.572; p=0.022) (Fig. 3). Pairwise 
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comparisons showed a statistically significant decrease of freezing levels between test 
sessions for both vehicle (PR-LTM24h vs PR-LTM8d, p=0.023) and AM251 treated rats (PR-
LTM24h vs PR-LTM8d, p=0.010). However, analysis of single sessions did not show a 
statistically significant differences in freezing response among groups 48h or 8d after 
conditioning (veh vs URB597 vs AM251, F2,21=0.414; p=0.666 and F2,21=1.563; p=0.233, 
respectively). Thus, 48h and 7d after conditioning the fear memory is still consolidated 
and was not altered by drug administrations. Subsequently, the decreasing effect of 
AM251 previously observed on freezing response is dependent on stimulus re-exposure 
during the memory reactivation session. 
 
Fig. 3 Effects of the indirect CB1 agonist URB597 (30ng/0.5ul) and the CB1 antagonist AM251 
(300ng/0.5ul) on CS–fear memory reconsolidation in rats not exposed to reactivation session. 
Administration of URB597 (30ng/0.5ul) or AM251 (300ng/0.5ul) in absence of memory reactivation 
had no effect on the retrieval of the CS–fear memory both 24h and 8d after administration. Data 
are presented as means ± SEM. Group sizes were veh, n = 8; URB597 (30ng/0.5ul), n = 8; AM251 
(300ng/0.5ul), n = 8. 
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GABAergic neurotransmission was necessary to disruption of memory reconsolidation 
induced by intra-BLA AM251 administration. 
In order to investigate the mechanisms underlying the disruptive effect on memory 
reconsolidation induced by blocking CB1 neurotransmission, interaction between 
endocannabinoid and GABAergic neurotransmission was evaluated. All rats had previously 
conditioned to CS, as all groups froze more during the CS presentation than to the context 
during the reactivation session (F1,34=184.041; p<0.001). ANOVA revealed a significant 
main effect of treatment (F3,34=3.122; p=0.039), a significant main effect of session 
(reactivation vs PR-LTM24h vs PR-LTM8d, F3,34=75.682; p<0.001) and a significant 
interaction session x treatment effect (F6,68=4.306; p=0.001) (Fig. 4). Pairwise comparisons 
showed a statistically significant decrease of freezing response between sessions for 
AM251-treated rats (PR-LTM24h vs reactivation, p<0.001; reactivation vs PR-LTM8d, 
p<0.001), for bicuculline infused rats(PR-LTM24h vs reactivation, p=0.011; PR-LTM8d vs 
reactivation, p<0.001), and for rats co-administered with AM251 and bicuculline (PR-
LTM8d vs reactivation, p=0.002). As previously, these differences indicate that the 
conditioned freezing response is progressively weakened after repeated exposure to the 
auditory stimuli in absence of the reinforcement. Interestingly, analysis of single sessions 
revealed that during the reactivation session there was not a statistically significance 
difference in freezing levels among groups in absence of the treatment (F3,34=1.27; 
p=0.300). However, single test sessions analysis, revealed that freezing response change 
significantly 24h and 8d after memory reactivation followed by drug infusions (F3,34=4.683; 
p=0.008). Post hoc showed that after 24h AM251 treated rats froze less when compared 
with vehicle, and bicuculline treated rats (p=0.029; p=0.017) and when compared with 
rats co-infused with AM251 and bicuculline (p=0.045). Thus, we replicated and confirmed 
the disruptive effect on memory reconsolidation induced by the CB1 receptor antagonist 
AM251. Moreover, we discovered that this disruptive effect was reverted by blocking the 
GABAA receptor activity. Here we showed that the disruptive effect on reconsolidated 
memories exerted by CB1 neurotransmission blockade is mediated by the GABAergic 
system. 
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Fig. 4 Effects of the CB1 antagonist AM251 (300ng/0.5ul) or the GABAA receptor antagonist 
bicuculline (Bic 50ng/0.5ul) on CS–fear memory reconsolidation Administration AM251 
(300ng/0.5ul) immediately after the reactivation session persistently impaired the CS–fear memory 
both 24h and 8d after the reactivation session ¤p<0.05 vs veh; ¶p<0.05 vs bic; #p<0.05 vs 
AM251+bic; ***p<0.001 PR-LTM24h vs reactivation and PR-LTM8d vs reactivation; $$$p<0.001 PR-
LTM8d vs reactivation; $p<0.05 PR-LTM24h vs reactivation; &&p<0.01 PR-LTM8d vs reactivation. 
Data are presented as means ± SEM. Group sizes were veh, n = 10; AM251 (300ng/0.5ul), n = 10; 
Bic (50ng/0.5ul), n = 10; AM251 (300ng/0.5ul)+ Bic (50ng/0.5ul), n = 8 
Discussion 
In this study we showed for the first time, to our knowledge, that blocking CB1 receptors 
directly in the BLA disrupted memory reconsolidation of CS-fear memory, based on a 
classical pavlovian associations between environmental conditioned stimuli (CSs) and 
negative reinforcer (unconditioned stimuli, or USs). This disruptive effect on memory 
reconsolidation, which persisted at least 8d after CS-re-exposure, occurred only when the 
CB1 receptor antagonist AM251 was infused locally in BLA immediately after retrieval. 
Administration of same drug at the same dose 30 min prior to memory reactivation did 
not induce an impairing effect on freezing response during retest 24h or 8d later. Local 
infusion of the indirect CB1 receptor agonist URB597 affected expression of fear memory 
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reconsolidation when it was administered prior to memory reactivation, on the other 
hand, it was able to induce only a transient enhancing effect on the freezing response 
when infused immediately after recall. Moreover, infusion of the same drug in non-
reactivated rats did not alter the conditioned freezing response, suggesting that the 
enhancement of memory reconsolidation is a retrieval-dependent process.  
Additionally, we investigated the mechanism underlying endocannabinoid signalling in 
BLA during memory reconsolidation. Katona and co-workers in 2001 showed that CB1 
receptors localize presynaptically in BLA on a distinct subpopulation of GABAergic 
interneurons suggesting that cannabinoids might alter inhibitory synaptic transmission 
(Katona et al, 2001). In this study, Katona and colleagues demonstrated that CB1 receptor 
activation inhibited GABA release, and that this effect was reverted by application of CB1 
receptor antagonist SR141716 (Katona et al, 2001). On the basis of these results, we 
hypothesised that potentiation of memory reconsolidation through endocannabinoid 
inactivation in BLA could be mediated by GABAergic signalling. Our hypothesis has been 
confirmed by local co-infusion of CB1 antagonist AM251 and receptor antagonist 
bicuculline. Indeed, blocking GABAA receptor-mediated signalling reverted the erasing 
effect on memory reconsolidation exerted by AM251, and re-established the expression 
of conditioned fear. 
These findings confirmed our hypothesis that the endocannabinoid system is importantly 
involved in regulation of memory reconsolidation process. Most importantly, our data 
suggest that inhibition or activation of GABAergic signalling in a cannabinoid-dependent 
manner might be a promising neurochemical substrate in modulation of emotional state 
and a new potential target for treatment of neuropsychiatric disorders, such as post-
traumatic stress disorder. 
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General discussion and conclusion 
The involvement of the endocannabinoid system in the modulation of emotion and 
cognition is broadly described in the literature (Abush et al, 2010; Akirav, 2011; Bortolato 
et al, 2006; Campolongo et al, 2013; Campolongo et al, 2012a; Campolongo et al, 2009a; 
Campolongo et al, 2009b; de Oliveira Alvares et al, 2010). During my PhD program I 
focused my attention on the investigation of the mechanisms involved in such 
modulation.  
Patel and coworkers (2003) demonstrated that systemic administration of propofol 
increased the levels of anandamide in mouse brain while administration of 
benzodiazepines, barbiturates, or volatile anaesthetics did not. Moreover, they showed 
that the effect of propofol on anandamide levels is mediated by an inhibition of the fatty 
acid amide hydrolase (FAAH) enzyme, the major degradation enzyme of anandamide and 
other related compounds. Based on these findings and on the evidence indicating that 
propofol is also associated with a higher incidence of traumatic memories from 
perioperative awareness and intensive care unit treatment (Kapfhammer et al, 2004b), 
we hypothesized that propofol administration could modulate the long-term retention of 
aversive memory. Our findings demonstrate that propofol, in contrast to other commonly 
used sedatives, enhanced memory consolidation when administered immediately after 
the exposure to an aversive event. Importantly, we demonstrated that this enhancing 
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effect on memory consolidation depends on an indirect activation of the 
endocannabinoid system as propofol effect on memory is blocked by co-administration of 
the CB1 receptor antagonist rimonabant. These findings indicate that propofol, at 
anaesthetic doses, enhances emotional memory consolidation when administered 
immediately after a stressful event by enhancing endocannabinoid signalling. On the 
other hand, we found that midazolam and pentobarbital, two sedative/anaesthetic drugs 
that do not increase endocannabinoid signalling (Patel et al, 2003), do not enhance the 
consolidation of memory for inhibitory avoidance training. In accordance with the 
behavioural data, we also found that propofol administration increases anandamide 
concentrations in the rat brain 8 min after injection, whereas anandamide plasma 
concentration remains unaffected. On the whole, our work strongly suggest that propofol 
should used with caution in individuals during the aftermath of an acute traumatic event 
and may help to explain the increased incidence of aversive memories from 
intraoperative awareness seen in patients undergoing total intravenous anaesthesia with 
propofol. 
Drugs that interfere with endocannabinoid degradation increase ongoing 
endocannabinoid signalling in a temporarily and spatially restricted manner (Janero et al, 
2009). However, cannabinoid effects on emotionality often exhibit a biphasic profile, as it 
is also reported by cannabis abusers (Curran et al, 2002; Fant et al, 1998; Hall and Solowij, 
1998). A classical model elucidates this phenomenon referring to the use of different 
doses of cannabinoid drugs, with low doses generally inducing anxiolytic-like effects and 
high doses often causing the opposite (Moreira and Wotjak, 2010). However, a wide 
numbers of studies report evidence that indirect cannabinoid receptor agonists can 
induce biphasic effects on behaviour, depending on the emotional state of the subject. 
Haller and co-workers (2009), for instance, have recently demonstrated that the indirect 
cannabinoid agonist URB597, a FAAH inhibitor responsible of endogenous cannabinoid 
degradation, did not affect anxiety under mildly stressful circumstances but has strong 
anxiolytic-like effects in highly aversive testing conditions . Therefore, a new and 
appealing explanation for the biphasic effects of cannabinoid drugs on behaviour, is now 
emerging, suggesting that these effects might also depend on previous experiences, the 
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context of use and the level of emotional arousal at the time of drug 
administration/consumption (Akirav, 2011; Campolongo et al, 2013; Sciolino et al, 
2011).This finding leaves open the possibility that inhibitors of endocannabinoid 
transport, which prolong endocannabinoid actions by preventing endocannabinoid access 
to intracellular hydrolyzing enzymes (Beltramo et al, 1997; Kathuria et al, 2003), may 
influence both emotional and cognitive processes depending on the level of 
environmental aversiveness at the time of drug administration. Thus, we investigated the 
effect of the prototypical endocannabinoid transport inhibitor AM404 in a non-aversive 
task, the Spatial Open Field test, under two experimental conditions which differed in the 
level of emotional arousal at the time of testing (Chapter 2). We found that different 
levels of environmental aversiveness strongly influence the emotional reactivity of 
untreated rats without affecting the cognitive performance. On the other hand, we found 
that AM404 effects on memory recognition strongly depends on the level of emotional 
arousal. 
There is evidence that behavioural responses to the environmental stimuli are strictly 
dependent on the emotional reactivity induced by the environment itself (Blanchard et al, 
2001; Haller et al, 2009). From an evolutionary point of view, the emotional arousal 
hailing from environmental context is crucially involved in assessing the novelty and 
salience of the external stimuli in terms of relevance for the adaptation and survival 
(Biegler and Morris, 1996; Breivogel et al, 1998; Poucet, 1993). Thus, when compared 
with a previous experience, a novel information recognized as highly relevant is 
committed to and stored by memory (Lemaire et al, 1999). For instance, Mumby and 
colleagues (2002) suggested that the impact of the object novelty is more salient than a 
spatial rearrangement with the same objects . That is why, probably, in our study 
untreated rats exposed to a high or to a low stressful experimental context were equally 
able to recognize the object substitution but failed to respond to the object displacement. 
However, we showed that AM404 administration impaired the capability to discriminate 
between a familiar and a new object in rats exposed to the highly arousal condition. These 
results strongly support the hypothesis that cannabinoids modulation of cognitive 
processes depend on the emotional state of the subject at the time of testing. Moreover, 
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we found that while AM404 administration did not influence object exploration in a 
context characterized by a low-level of emotional activation, rats treated with a low dose 
of AM404 and exposed to a more stressful environment spent less time investigating the 
objects, whereas a higher doses re-established the investigation activity at similar level of 
the vehicle-treated rats. The inhibition or the maintenance of the investigative behaviour 
can be related to an anxiogenic or an anxiolytic phenotype, respectively (Crawley, 1985). 
It is possible to speculate that this biphasic effect may depend on a differential regulation 
activity on both GABAergic and gutamatergic neurons mediated by different doses of the 
endocannabinoid transport inhibitor (Foldy et al, 2007; Hashimotodani et al, 2007). This 
interpretation seems to be in accordance with previous studies showing that the 
activation of the CB1 receptor results in a reduction of neurotransmitter release from the 
pre-synaptic terminal by a retrograde mechanism (Wilson and Nicoll, 2002). Furthermore, 
Laaris and co-workers (2010) report that direct cannabinoid receptor agonists Δ9-THC 
inhibits GABA release (Laaris et al, 2010). Additionally, other researchers showed a CB1 
receptor-mediated inhibition for glutamate release both in rats (Hoffman et al, 2010; 
Wang, 2003) and mice (Kawamura et al, 2006). The opposite effects due to GABA and 
glutamatergic circuits could be explained by a different basal activation of the CB1 
receptors expressed on these sub-populations of neurons. The basal activation of the CB1 
receptors on glutamatergic synapses, which is lower than the basal CB1 receptors 
activation on GABA, suggests that the reactivity to an increase in the endocannabinoid 
tone could make more sensitive glutamatergic neurons than GABAergic neurons (Katona 
and Freund, 2008). Thus, a minimal increase in endocannabinoid levels could inhibit the 
release of glutamatergic neurotransmitters and impair the approaching behaviour 
response, while a higher amount of endocannabinoids could activate the inhibition of the 
GABA terminal leading to the opposite effect.  
It is well established that the hypothalamic-pituitary-adrenal (HPA) axis plays a crucial role 
in stress response and that the stress hormones, such as glucocorticoids, differentially 
modulate cognitive functions (Atsak et al, 2011; Mizoguchi et al, 2004; Roozendaal and 
McGaugh, 1997). Most importantly, modulation of memory consolidation processes is 
clearly affected by manipulation of endocannabinoid signalling via a cross-talk with the 
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glucocorticoid system (Atsak et al, 2011; Campolongo et al, 2013; Campolongo et al, 
2009a; Campolongo et al, 2009b). These results highlight that drugs enhancing 
endocannabinoid signalling by interfering with endocannabinoid deactivation induce 
different effects on short-term memory performance depending on the level of emotional 
arousal induced by different environmental settings. 
In Chapter 3 and 4 it has been evaluated the effect of pharmacological manipulation in 
the basolateral amygdala on memory reconsolidation. The behavioral paradigm which 
more than other is well suits for neurobiological analysis in this context is represented by 
Pavlovian fear conditioning. Fear conditioning is valuable as a neurobiological tool 
because it involves a specific stimulus, under the control of the experimenter, that reliably 
elicits a measurable set of behavioural and physiological responses once learning has 
occurred. In fear conditioning, an emotionally neutral conditioned stimulus, such as a 
tone, is paired with an emotionally potent, innately aversive unconditioned stimulus (e.g., 
an electric shock) during a conditioning or acquisition phase. 
Considerable evidence indicate the BLA as a critical region for the encoding of associative 
memories relevant to affective experiences (Aggleton, 2000; Rosenkranz and Grace, 
2002).  
The first step required for memory reconsolidation is the destabilization induced by 
retrieval which converted a previously consolidated memory from the ‘inactive state’ in to 
the ‘active state’. These ‘active’ memories are newly restabilized back into the ‘inactive’ 
state (reconsolidated) through a protein-synthesis dependent process. Thus, disrupting 
reconsolidation appears to be a valuable target, in terms of therapeutic strategy, in order 
to reduce the impact of maladaptive memories on behavior.  
It is known that NMDAR-mediated signaling is necessary for 
reconsolidation/restabilization of CS-drug (Brown et al, 2008; Itzhak, 2008; Milton et al, 
2008b; Milton et al, 2012; Sadler et al, 2007), spatial (Przybyslawski and Sara, 1997) and 
CS-fear (Lee et al, 2006c; Pedreira et al, 2002) memories. However, this seems to be in 
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contrast with other findings showing that pharmacological blockade of GluN2B subtype of 
NMDAR has been shown to prevent the destabilization of CS-fear memories (Ben Mamou 
et al, 2006). We recently showed that GluN2B-NMDARs GluN2B-NMDARs and GluN2A-
NMDARs are differently involved in the regulation of memory reconsolidation where 
GluN2B-NMDARs is required for memory destabilization while GluN2A-NMDARs is 
required for memory restabilization (Chapter 3). Our results are supported by previous 
findings showing that GluN2A-preferring NMDAR antagonists prevent the acquisition of 
spatial memory (Hu et al, 2009) and conditioned fear (Dalton et al, 2012).  
Increasing clinical evidence links disturbances in endocannabinoid transmission with the 
etiology of psychopathologies, which are characterized by profound disturbances in 
emotional regulation disorders (Bangalore et al, 2008; Cohen et al, 2008; Schneider, 
2008). CB1 receptor expression is found in relatively high concentrations in the BLA 
(McDonald and Mascagni, 2001; Tsou et al, 1998), and, most particularly, within the BLA, 
CB1 receptors are found on inhibitory local GABAergic interneurons (Herkenham et al, 
1990; Katona et al, 2001; Tsou et al, 1998). Functionally, activation of BLA CB1 receptors 
decreases feedforward inhibition via inhibitory interneurons, thereby increasing the 
activity of BLA projection neurons (Pistis et al, 2004). Given that both recall and extinction 
of conditioned fear memories are correlated with increased release of intra-BLA 
endocannabinoids (Marsicano et al, 2002), this suggests a critical role for intra-BLA CB1 
transmission during the processing of emotionally salient information. In chapter 4, we 
showed that CB1-mediated transmission modulates reconsolidation of pavlovian fear 
memory and that this neurotransmission is mediated by GABAergic signalling in BLA. 
Interestingly, we found that pharmacological manipulation of CB1 receptor induced a 
bidirectional effect on expression of fear response, where the indirect agonist URB597 
positively modulates memory reconsolidation, while administration of the CB1-receptor 
antagonist AM251 disrupt retention of fear memory. These findings are in line with 
previous observations which showing that the indirect cannabinoid agonist URB597, 
bilaterally infused in BLA enhanced consolidation for aversive memory and this effect is 
prevented by blocking CB1 receptors with infusion of the CB1 receptor antagonist AM251 
(Ratano et al, 2011). Interestingly, we found that the AM251-dependent disruptive effect 
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is abolished by co-infusion with GABAAreceptor antagonist bicuculline, consistently with 
data revealing the local expression of CB1 receptors on subpopulation of GABAergic 
neurons in the BLA.  
All together these evidence confirm that the endocannabinoid system is crucially involved 
in the regulation of emotional memory processing. Thus, it is reasonable to hypothesize 
that targeting cannabinoid neurotransmission could represent a powerful therapeutic tool 
in treating cognitive disorders linked to emotional distress. 
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